Document:

EX-10.1

 Exhibit 10.1 

SECURITIES PURCHASE AGREEMENT 

This Securities Purchase Agreement (this “Agreement”) is dated as of May 12, 2021 (the “Effective
Date”), among Magenta Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each a “Purchaser” and, collectively, the
“Purchasers”). 
 WHEREAS, the Company and the Purchasers are executing and delivering this Agreement in reliance
upon the exemption from securities registration afforded by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). 

WHEREAS, each Purchaser wishes to purchase, and the Company wishes to sell, upon the terms and conditions stated in this Agreement, the number
of shares of Common Stock set forth opposite such Purchaser’s name on Exhibit A hereto, which aggregate number of shares of Common Stock for all Purchasers together shall be 9,599,998 shares of Common Stock (the
“Shares”). 
 NOW, THEREFORE, in consideration of the mutual covenants
contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which are hereby acknowledged, the Company and each Purchaser, severally and not jointly, agree as follows: 

 

	1.	 DEFINITIONS 

1.1    Definitions. In addition to the terms defined elsewhere in this Agreement, the following terms have
the meanings set forth in this Section 1.1: 
 “Closing” means the closing of the purchase
and sale of the Shares on the Closing Date pursuant to Section 2.1 of this Agreement. 
 “Closing
Date” means May 14, 2021. 
 “Commission” means the United States Securities and Exchange
Commission. 
 “Common Stock” means the common stock of the Company, $0.001 par value per share, and any other class
of securities into which such securities may hereafter be reclassified or changed into. 
 “Exchange Act” means the
Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder. 
 “GAAP” means
U.S. generally accepted accounting principles consistently applied. 
 “Investment Company Act” means the Investment
Company Act of 1940, as amended. 
 “Material Adverse Effect” means a circumstance that (i) could reasonably be
expected to have a material adverse effect on the performance of this Agreement or the consummation of any of the transactions contemplated hereby or (ii) could reasonably be expected to have a material adverse effect on the condition
(financial or otherwise), earnings, results of operations, business, prospects or properties of the Company and the Subsidiaries (as defined below) taken as a whole. 

  
 1 

 “Nasdaq” means The Nasdaq Global Market. 

“Rule 144” means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same effect as such Rule. 

“SEC Reports” means collectively all reports, schedules, forms, statements and other documents filed or furnished by
the Company under the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, since January 1, 2020 (including the exhibits thereto and documents incorporated by reference therein). 

“Short Sales” means all “short sales” as defined in Rule 200 of Regulation SHO of the Exchange Act, but
shall be deemed to not include the location and/or reservation of borrowable shares of Common Stock. 

“Subsidiaries” means any subsidiary of the Company. 

“Trading Day” means a day on which the Common Stock is traded on Nasdaq. 

“Transaction Documents” means this Agreement, and any other documents or agreements executed and delivered to the
Purchasers in connection with the transactions contemplated hereunder. 
  

	2.	 PURCHASE AND SALE 

2.1    Closing. 

(a)    At the Closing, upon the terms set forth herein, the Company hereby agrees to issue and sell to each
Purchaser, and each Purchaser agrees to purchase from the Company, severally and not jointly, the number of Shares set forth opposite such Purchaser’s name on Exhibit A hereto, at a purchase price equal to $9.00 per share of Common
Stock. 
 (b)    At the Closing, each Purchaser shall deliver to the Company via wire transfer of immediately
available funds equal to the purchase price set forth opposite such Purchaser’s name on Exhibit A hereto and the Company shall deliver to each Purchaser its respective Shares in the amount set forth opposite such Purchaser’s name on
Exhibit A hereto, deliverable at the Closing on the Closing Date, in accordance with Section 2.2 of this Agreement. The Closing shall take place remotely via the exchange of executed documents and funds at 10:00 a.m. (New
York City Time) on the Closing Date or such other time and location as the parties shall mutually agree. 

2.2    Deliveries; Closing Conditions. 

(a)    At the Closing, the Company will deliver or cause to be delivered to each Purchaser certificate(s) or
book-entry shares representing the Common Stock, purchased by such Purchaser, registered in such Purchaser’s name. Such delivery shall be against payment of the purchase price therefor by such Purchaser by wire transfer of immediately available
funds to the Company in accordance with the Company’s written wiring instructions. 

  
 2 

 (b)    The respective obligations of the Company, on the one
hand, and each Purchaser, on the other hand, hereunder in connection with the Closing are subject to the following conditions being met: 

(i)    the accuracy in all material respects on the Closing Date of the representations and warranties contained
herein (unless made as of a specified date therein) of the Company (with respect to the obligations of the Purchasers) and the Purchasers (with respect to the obligations of the Company); 

(ii)    all obligations, covenants and agreements of the Company (with respect to the obligations of the
Purchasers) and the Purchasers (with respect to the obligations of the Company) required to be performed at or prior to the Closing Date shall have been performed in all material respects; 

(iii)    the Purchasers shall have received a certificate of the Secretary of the Company (a
“Secretary’s Certificate”), dated as of the Closing Date, in form and substance reasonably satisfactory to the Purchasers; 

(iv)    the Purchasers shall have received a certificate signed by the Chief Executive Officer of the Company (an
“Officer’s Certificate”), dated as of the Closing Date, in form and substance reasonably satisfactory to the Purchasers; 

(v)    the Purchasers shall have received an opinion of Goodwin Procter LLP, counsel for the Company, dated as of
the Closing Date, in a form reasonably satisfactory to the Purchasers; and 
 (vi)    no Material Adverse Effect
has occurred. 
  

	3.	 REPRESENTATIONS AND WARRANTIES 

3.1    Representations and Warranties of the Company. Assuming the accuracy of the representations and
warranties of the Purchasers set forth in Section 3.2 of this Agreement and except as set forth in the SEC Reports, which disclosures serve to qualify these representations and warranties in their entirety, the Company
represents and warrants to the Purchasers that the statements contained in this Section 3.1 are true and correct as of the date hereof and as of the Closing Date (except for the representations and warranties that speak as
of a specific date, which shall be made as of such date): 
 (a)    The Company was not and is not an Ineligible
Issuer (as defined in Rule 405 under the Securities Act), without taking account of any determination by the Commission pursuant to Rule 405 that it is not necessary that the Company be considered an Ineligible Issuer. 

(b)    The Company has been duly incorporated and is validly existing as a corporation in good standing under the
laws of the State of Delaware, with full corporate power and authority to own, lease and operate its properties and conduct its business, to execute and deliver this Agreement and to issue, sell and deliver the Shares as contemplated herein. 

  
 3 

 (c)    The Company is duly qualified to do business as a foreign
corporation and is in good standing in the Commonwealth of Massachusetts, which is the only jurisdiction where the ownership or leasing of its properties or the conduct of its business requires such qualification, except where the failure to be so
qualified and in good standing would not, individually or in the aggregate, have a Material Adverse Effect. 

(d)    The authorized capital stock of the Company consists of 150,000,000 shares of Common Stock and 10,000,000
shares of undesignated preferred stock, par value $0.001 per share (the “Preferred Stock”). As of May 8, 2021, there are no shares of Preferred Stock issued and outstanding and there are 48,610,659 shares of Common Stock
issued and outstanding, of which no shares are owned by the Company. There are no other shares of any other class or series of capital stock of the Company issued or outstanding. 

(e)    The Company has no Subsidiaries other than Magenta Securities Corporation. The Company owns all of the
issued and outstanding capital stock and ownership interests of the Subsidiaries. Other than the capital stock and ownership interests of the Subsidiaries, the Company does not own, directly or indirectly, any shares of stock or any other equity
interests or long-term debt securities of any corporation, firm, partnership, joint venture, association or other entity. Each of the Subsidiaries has been duly incorporated and is validly existing as a corporation and is in good standing
under the laws of the Commonwealth of Massachusetts, with full corporate power and authority to own, lease and operate its properties and to conduct its business; each Subsidiary is duly qualified to do business as a foreign corporation and is in
good standing in each jurisdiction where the ownership or leasing of its properties or the conduct of its business requires such qualification, except where the failure to be so qualified and in good standing would not, individually or in the
aggregate, have a Material Adverse Effect; all of the outstanding shares of capital stock and ownership interests of the Subsidiaries have been duly authorized and validly issued, are fully paid and
non-assessable, have been issued in compliance with all applicable securities laws, were not issued in violation of any preemptive right, resale right, right of first refusal or similar right and are owned by
the Company subject to no security interest, other encumbrance or adverse claims; and no options, warrants or other rights to purchase, agreements or other obligations to issue or other rights to convert any obligation into shares of capital stock
or ownership interests in the Subsidiaries are outstanding. 
 (f)    The Shares have been duly and validly
authorized and, when issued and delivered against payment therefor as provided herein, will be duly and validly issued, fully paid and non-assessable and will conform in all material respects to the
descriptions thereof in the SEC Reports; and the issuance of the Shares is not subject to any preemptive or similar rights that have not been duly waived or satisfied. 

(g)    This Agreement has been duly authorized, executed and delivered by the Company and constitutes the lawful,
valid and legally binding obligation of the Company, enforceable in accordance with its terms, except as enforceability may be limited by bankruptcy, insolvency, reorganization or similar laws affecting the rights of creditors generally and as
limited by general equitable principles. 

  
 4 

 (h)    Neither the Company nor its Subsidiaries is (i) in
violation of its charter or by-laws or similar organizational documents; (ii) in default, and no event has occurred that, with notice or lapse of time or both, would constitute such a default, in the due
performance or observance of any term, covenant or condition contained in any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which the Company or its Subsidiaries are a party or by which the Company or its
Subsidiaries are bound or to which any property or asset of the Company or its Subsidiaries are subject; or (iii) in violation of any law or statute or any judgment, order, rule or regulation of any court or arbitrator or governmental or
regulatory authority, except, in the case of clauses (ii) and (iii) above, for any such default or violation that would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. 

(i)    The Company is not and, after giving effect to the offering and sale of the Shares and the application of
the proceeds thereof, will not be required to register as an “investment company” or an entity “controlled” by an “investment company,” as such terms are defined in the Investment Company Act. 

(j)    The execution, delivery and performance by the Company of this Agreement, the issuance and sale of the
Shares and the consummation of the transactions contemplated by this Agreement will not (i) conflict with or result in a breach or violation of any of the terms or provisions of, or constitute a default under, result in the termination,
modification or acceleration of, or result in the creation or imposition of any lien, charge or encumbrance upon any property, right or asset of the Company or its Subsidiaries pursuant to, any indenture, mortgage, deed of trust, loan agreement or
other agreement or instrument to which the Company or its Subsidiaries are a party or by which the Company or its Subsidiaries are bound or to which any property, right or asset of the Company or its Subsidiaries are subject, (ii) result in any
violation of the provisions of the charter or by-laws or similar organizational documents of the Company or its Subsidiaries or (iii) result in the violation of any law or statute or any judgment, order,
rule or regulation of any court or arbitrator or governmental or regulatory authority, except, in the case of clauses (i) and (iii) above, for any such conflict, breach, violation, default, lien, charge or encumbrance that would not,
individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. 
 (k)    No consent,
approval, authorization, order, registration or qualification of or with any court or arbitrator or governmental or regulatory authority is required for the execution, delivery and performance by the Company of this Agreement, the issuance and sale
of the Shares and the consummation of the transactions contemplated by this Agreement, other than (i) any necessary qualification under the securities or blue sky laws of the various jurisdictions in which the Shares are being offered,
(ii) any listing applications and related consents (which, for avoidance of doubt, does not include any consent of the Company’s stockholders) or any notices required by Nasdaq in the ordinary course of the offering of the Shares,
(iii) filings with the Commission under the Securities Act contemplated by this Agreement or (iv) filings with the Commission on Form 8-K with respect to this Agreement. 

(l)    No person has the right to require the Company or any of its Subsidiaries to register any securities for
sale under the Securities Act by reason of the filing of the Resale Registration Statement (as defined below) with the Commission or the issuance and sale of the Shares, other than those rights that have been validly waived. 

  
 5 

 (m)    The Company and its Subsidiaries possess all licenses, sub-licenses, certificates, permits and other authorizations issued by, and have made all declarations and filings with, the appropriate federal, state, local or foreign governmental or regulatory authorities that
are necessary for the ownership or lease of their respective properties or the conduct of their respective businesses, except where the failure to possess or make the same would not, individually or in the aggregate, reasonably be expected to have a
Material Adverse Effect; and neither the Company nor its Subsidiaries have received written notice of any revocation or modification of any such license, sub-license, certificate, permit or authorization or
has any reason to believe that any such license, sub-license, certificate, permit or authorization will not be renewed in the ordinary course, except where such revocation, modification, or non-renewal would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. 

(n)    The SEC Reports, when they were filed with the Commission, conformed in all material respects to the
requirements of the Exchange Act and none of the SEC Reports, when filed with the Commission, contained any untrue statement of a material fact or omitted to state a material fact necessary to make the statements therein, in the light of the
circumstances under which they were made, not misleading. 
 (o)    No relationship, direct or indirect, exists
between or among the Company or its Subsidiaries, on the one hand, and the directors, officers, stockholders, customers or suppliers of the Company or its Subsidiaries, on the other, that is required by the Securities Act to be described in the SEC
Reports and that is not so described in such documents. 
 (p)    The financial statements (including the related
notes thereto) of the Company and its consolidated Subsidiaries included or incorporated by reference in the SEC Reports comply in all material respects with the applicable requirements of the Securities Act and the Exchange Act, as applicable, and
present fairly in all material respects the financial position of the Company and its consolidated Subsidiaries as of the dates indicated and the results of their operations and the changes in their cash flows for the periods specified; such
financial statements have been prepared in conformity with GAAP in the United States applied on a consistent basis throughout the periods covered thereby, except in the case of unaudited financial statements, which are subject to normal year-end adjustments and do not contain certain footnotes as permitted by the applicable rules of the Commission; and any supporting schedules included or incorporated by reference in the SEC Reports present fairly
in all material respects the information required to be stated therein; and the other financial information included or incorporated by reference in the SEC Reports has been derived from the accounting records of the Company and its consolidated
Subsidiaries and presents fairly in all material respects the information shown thereby. 
 (q)    Except as
described in the SEC Reports, there are no legal, governmental or regulatory investigations, actions, demands, claims, suits, arbitrations, inquiries or proceedings (“Actions”) pending to which the Company or its Subsidiaries
are or may reasonably be expected to become a party or to which any property of the Company or its Subsidiaries are or may reasonably be expected to become the subject that, individually or in the aggregate, if determined adversely to the Company or
its Subsidiaries, would reasonably be expected to have a Material 

  
 6 

 
Adverse Effect; to the knowledge of the Company, no such Actions are threatened or contemplated by any governmental or regulatory authority; and (i) there are no current or pending Actions
that are required under the Securities Act to be described in the SEC Reports that are not so described in the SEC Reports and (ii) there are no statutes, regulations or contracts or other documents that are required under the Securities Act to
be filed as exhibits to the SEC Reports that are not so filed as exhibits to the SEC Reports or described in the SEC Reports. 

(r)    KPMG LLP, who have certified certain financial statements of the Company and its Subsidiaries, is an
independent registered public accounting firm with respect to the Company and its Subsidiaries within the applicable rules and regulations adopted by the Commission and the Public Company Accounting Oversight Board (United States) and as required by
the Securities Act. 
 (s)    With respect to the stock options (the “Stock Options”)
granted pursuant to the stock-based compensation plans of the Company and its Subsidiaries existing as of the date hereof (the “Company Stock Plans”), (i) each Stock Option intended to qualify as an “incentive stock
option” under Section 422 of the Internal Revenue Code of 1986, as amended (the “Code”), so qualifies, (ii) each grant of a Stock Option was duly authorized no later than the date on which the grant of such
Stock Option was by its terms to be effective by all necessary corporate action, including, as applicable, approval by the board of directors of the Company (or a duly constituted and authorized committee thereof) and any required stockholder
approval by the necessary number of votes or written consents, and the award agreement governing such grant (if any) was duly executed and delivered by each party thereto, (iii) each such grant was made in accordance with the terms of the
Company Stock Plans and all other applicable laws and regulatory rules or requirements, including the rules of Nasdaq and any other exchange on which Company securities are traded, and (iv) each such grant was properly accounted for in
accordance with GAAP in the financial statements (including the related notes) of the Company and disclosed in the Company’s filings with the Commission in accordance with the Exchange Act and other applicable laws. The Company has not
knowingly granted, and there is no and has been no policy or practice of the Company of granting, Stock Options prior to, or otherwise coordinating the grant of Stock Options with, the release or other public announcement of material information
regarding the Company or its Subsidiaries or their results of operations or prospects. 
 (t)    Since the date
of the most recent financial statements of the Company included or incorporated by reference in the SEC Reports, (i) there has not been any change in the capital stock (other than the issuance of shares of Common Stock upon exercise of stock
options and warrants described as outstanding in, and the grant of options and awards under existing equity incentive plans described in, the SEC Reports), short-term debt or long-term debt of the Company or its Subsidiaries, or any dividend or
distribution of any kind declared, set aside for payment, paid or made by the Company on any class of capital stock, or any material adverse change, or any development that would reasonably be expected to result in a prospective material adverse
change, in or affecting the business, properties, management, financial position, stockholders’ equity, results of operations or prospects of the Company and its Subsidiaries taken as a whole; (ii) neither the Company nor its Subsidiaries
has entered into any transaction or agreement (whether or not in the ordinary course of business) that is material to the Company and its Subsidiaries taken as a whole or incurred any liability or obligation, direct or contingent, that is material
to the Company and its Subsidiaries taken as a whole; and (iii) neither the Company nor its Subsidiaries has 

  
 7 

 
sustained any loss or interference with its business that is material to the Company and its Subsidiaries taken as a whole and that is either from fire, explosion, flood or other calamity,
whether or not covered by insurance, or from any labor disturbance or dispute or any action, order or decree of any court or arbitrator or governmental or regulatory authority, except in each case as otherwise disclosed in the SEC Reports. 

(u)    The Company and its Subsidiaries own, or have valid rights to lease or otherwise use, all items of real and
personal property that are material to the respective businesses of the Company and its Subsidiaries, in each case, free and clear of all liens, encumbrances, claims and defects and imperfections of title except those that (i) do not materially
interfere with the use made and proposed to be made of such property by the Company and its Subsidiaries or (ii) could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect. 

(v)    Except as could not reasonably be expected, individually or in the aggregate, to have a Material Adverse
Effect: (i) the Company and its Subsidiaries own or have a valid and enforceable license to use all patents, trademarks, service marks, trade names, domain names and other source indicators, copyrights and copyrightable works, inventions, know-how, trade secrets, systems, procedures, proprietary or confidential information and all other worldwide intellectual property, industrial property and proprietary rights (including all registrations and
applications for registration of, and all goodwill associated with, any of the foregoing, as applicable) (collectively, “Intellectual Property”) used in, held for use in, or, to Company’s knowledge, necessary for the
conduct of their respective businesses; (ii) to the knowledge of the Company, the Company and its Subsidiaries have not infringed, misappropriated or otherwise violated any Intellectual Property right of any person or entity, and neither the
sale, use nor other exploitation of any of the discoveries, inventions, products, product candidates, services or processes of the Company or any of its Subsidiaries that are referred to in the SEC Reports do or will infringe, misappropriate or
otherwise violate any Intellectual Property right of any person or entity; (iii) there is no pending, or to the Company’s knowledge, threatened, action, suit, proceeding or claim by any person or entity (A) alleging that the Company
or any of its Subsidiaries has infringed, misappropriated or otherwise violated any Intellectual Property rights of any person or entity or (B) challenging the ownership, inventorship, validity, enforceability or scope of, or any of the rights
of the Company or any of its Subsidiaries in, any Intellectual Property owned by or licensed to the Company or any of its Subsidiaries; (iv) to the knowledge of the Company, none of the Intellectual Property owned by or licensed to the Company
or any of its Subsidiaries is being infringed, misappropriated or otherwise violated by any person or entity; and (v) each agreement pursuant to which the Company or any of its Subsidiaries obtains any license or other rights to any
Intellectual Property is a valid and binding agreement of the Company and its Subsidiaries and is in full force and effect, and none of the Company or any of its Subsidiaries or, to the knowledge of the Company, any other party thereto, is in
default or breach under any terms of any such agreement and, to the knowledge of the Company, no event or circumstance has occurred that, with notice or lapse of time or both, would constitute any event of default thereunder. 

(w)    (i)(x) Except as disclosed in the SEC Reports, there has been no security breach or other
compromise of or relating to any of the Company’s or its Subsidiaries’ information technology and computer systems, networks, hardware, software, data (including the data of their respective customers, employees, suppliers, vendors and any
third party data maintained by or on behalf of them), equipment or technology (collectively, “IT Systems and Data”) and (y) the 

  
 8 

 
Company and its Subsidiaries have not been notified of, and have no knowledge of any event or condition that would reasonably be expected to result in, any security breach or other compromise to
their IT Systems and Data; (ii) the Company and its Subsidiaries are presently in compliance with all applicable laws or statutes and all judgments, orders, rules and regulations of any court or arbitrator or governmental or regulatory
authority, internal policies and contractual obligations relating to the privacy and security of IT Systems and Data and to the protection of such IT Systems and Data from unauthorized use, access, misappropriation or modification, except as would
not, in the case of this clause (ii), individually or in the aggregate, have a Material Adverse Effect; and (iii) the Company and its Subsidiaries have implemented backup and disaster recovery technology consistent with industry standards and
practices. 
 (x)    No labor disturbance by or dispute with employees of the Company or its Subsidiaries exists
or, to the knowledge of the Company, is contemplated or threatened, and the Company is not aware of any existing or imminent labor disturbance by, or dispute with, the employees of its or its Subsidiaries’ principal suppliers, contractors or
customers, except as would not reasonably be expected to have a Material Adverse Effect. Neither the Company nor its Subsidiaries have received any notice of cancellation or termination with respect to any collective bargaining agreement to which it
is a party. 
 (y)    (i) Each employee benefit plan, within the meaning of Section 3(3) of the
Employee Retirement Income Security Act of 1974, as amended (“ERISA”), for which the Company or any member of its “Controlled Group” (defined as any entity, whether or not incorporated, that is under common control
with the Company within the meaning of Section 4001(a)(14) of ERISA or any entity that would be regarded as a single employer with the Company under Section 414(b),(c),(m) or (o) of the Code)) would have any liability (each, a
“Plan”) has been maintained in compliance with its terms and the requirements of any applicable statutes, orders, rules and regulations, including but not limited to ERISA and the Code; (ii) no prohibited transaction
within the meaning of Section 406 of ERISA or Section 4975 of the Code, has occurred with respect to any Plan, excluding transactions effected pursuant to a statutory or administrative exemption; (iii) for each Plan that is subject to
the funding rules of Section 412 of the Code or Section 302 of ERISA, no Plan has failed (whether or not waived), or is reasonably expected to fail, to satisfy the minimum funding standards (within the meaning of Section 302 of ERISA
or Section 412 of the Code) applicable to such Plan; (iv) no Plan is, or is reasonably expected to be, in “at risk status” (within the meaning of Section 303(i) of ERISA) and no Plan that is a “multiemployer plan”
within the meaning of Section 4001(a)(3) of ERISA is in “endangered status” or “critical status” (within the meaning of Sections 304 and 305 of ERISA); (v) the fair market value of the assets of each Plan exceeds the
present value of all benefits accrued under such Plan (determined based on those assumptions used to fund such Plan); (vi) no “reportable event” (within the meaning of Section 4043(c) of ERISA and the regulations promulgated
thereunder) has occurred or is reasonably expected to occur; (vii) each Plan that is intended to be qualified under Section 401(a) of the Code is so qualified, and nothing has occurred, whether by action or by failure to act, which would
cause the loss of such qualification; (viii) neither the Company nor any member of the Controlled Group has incurred, nor reasonably expects to incur, any liability under Title IV of ERISA (other than contributions to the Plan or premiums to
the Pension Benefit Guarantee Corporation, in the ordinary course and without default) in respect of a Plan (including a “multiemployer plan” within the meaning of Section 4001(a)(3) of ERISA); and (ix) none of the following
events has occurred or is reasonably 

  
 9 

 
likely to occur: (A) a material increase in the aggregate amount of contributions required to be made to all Plans by the Company or its Controlled Group affiliates in the current fiscal
year of the Company and its Controlled Group affiliates compared to the amount of such contributions made in the Company’s and its Controlled Group affiliates’ most recently completed fiscal year; or (B) a material increase in the
Company and its subsidiaries’ “accumulated post-retirement benefit obligations” (within the meaning of Accounting Standards Codification Topic 715-60) compared to the amount of such
obligations in the Company and its subsidiaries’ most recently completed fiscal year, except in each case with respect to the events or conditions set forth in (i) through (ix) hereof, as would not, individually or in the aggregate,
have a Material Adverse Effect. 
 (z)    (i) The Company and its Subsidiaries (x) are in compliance with
all, and have not violated any, applicable federal, state, local and foreign laws (including common law), rules, regulations, requirements, decisions, judgments, decrees, orders and other legally enforceable requirements relating to pollution or the
protection of human health or safety, the environment, natural resources, hazardous or toxic substances or wastes, pollutants or contaminants (collectively, “Environmental Laws”); (y) have received and are in compliance with
all, and have not violated any, permits, licenses, certificates or other authorizations or approvals required of them under any Environmental Laws to conduct their respective businesses; and (z) have not received written notice of any actual or
potential liability or obligation under or relating to, or any actual or potential violation of, any Environmental Laws, including for the investigation or remediation of any disposal or release of hazardous or toxic substances or wastes, pollutants
or contaminants, and have no knowledge of any event or condition that would reasonably be expected to result in any such notice; (ii) there are no costs or liabilities associated with Environmental Laws of or relating to the Company or its
Subsidiaries, except in the case of each of (i) and (ii) above, for any such matter as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; and (iii) except as described in the SEC Reports,
(x) there is no proceeding that is pending, or that is known by the Company to be contemplated, against the Company or its Subsidiaries under any Environmental Laws in which a governmental entity is also a party, other than such proceeding
regarding which the Company reasonably believes no monetary sanctions of $100,000 or more will be imposed, (y) the Company and its Subsidiaries are not aware of any facts or issues regarding compliance with Environmental Laws, or liabilities or
other obligations under Environmental Laws or concerning hazardous or toxic substances or wastes, pollutants or contaminants, that could reasonably be expected to have a material effect on the capital expenditures, earnings or competitive position
of the Company and its Subsidiaries, and (z) neither the Company nor its Subsidiaries anticipate material capital expenditures relating to any Environmental Laws. 

(aa)    The Company and its Subsidiaries have paid all federal, state, local and foreign taxes and filed all tax
returns required to be paid or filed through the date hereof, except for taxes being contested in good faith and for which reserves in accordance with GAAP in the United States have been taken; and except as otherwise disclosed in the SEC Reports,
and there is no tax deficiency that has been, or could reasonably be expected to be, asserted against the Company or its Subsidiaries or any of their respective properties or assets that would reasonably be expected to have a Material Adverse
Effect. 

  
 10 

 (bb)    The Company and its Subsidiaries have insurance covering
their respective properties, operations, personnel and businesses, including business interruption insurance, which insurance is in amounts and insures against such losses and risks which the Company reasonably believes are adequate to protect the
Company and its Subsidiaries and their respective businesses; and neither the Company nor its Subsidiaries have (i) received notice from any insurer or agent of such insurer that capital improvements or other expenditures are required or
necessary to be made in order to continue such insurance or (ii) any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage at reasonable cost from
similar insurers as may be necessary to continue its business. 
 (cc)    The Company and its Subsidiaries
maintain systems of “internal control over financial reporting” (as defined in Rule 13a-15(f) of the Exchange Act) that have been designed to comply with the requirements of the Exchange Act and have
been designed by, or under the supervision of, their respective principal executive and principal financial officers, or persons performing similar functions, to provide reasonable assurance regarding the reliability of financial reporting and the
preparation of financial statements for external purposes in accordance with GAAP. The Company and its Subsidiaries maintain internal accounting controls sufficient to provide reasonable assurance that (i) transactions are executed in
accordance with management’s general or specific authorizations; (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability; (iii) access to
assets is permitted only in accordance with management’s general or specific authorization; (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with
respect to any differences; and (v) interactive data in eXtensible Business Reporting Language included or incorporated by reference in the SEC Reports fairly presents the information called for in all material respects and is prepared in
accordance with the Commission’s rules and guidelines applicable thereto. Except as disclosed in the SEC Reports, there are no material weaknesses in the Company’s internal controls. The Company’s auditors and the Audit Committee of
the Board of Directors of the Company have been advised of: (i) all significant deficiencies and material weaknesses, if any, in the design or operation of internal controls over financial reporting which have adversely affected or are
reasonably likely to adversely affect the Company’s ability to record, process, summarize and report financial information; and (ii) any fraud, whether or not material, that involves management or other employees who have a significant
role in the Company’s internal controls over financial reporting. 
 (dd)    The Company and its
Subsidiaries maintain an effective system of “disclosure controls and procedures” (as defined in Rule 13a-15(e) of the Exchange Act) that has been designed to comply with the requirements of the
Exchange Act and that has been designed to ensure that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified
in the Commission’s rules and forms, including controls and procedures designed to ensure that such information is accumulated and communicated to the Company’s management as appropriate to allow timely decisions regarding required
disclosure. The Company and its Subsidiaries have carried out evaluations of the effectiveness of their disclosure controls and procedures as required by Rule 13a-15 of the Exchange Act. 

  
 11 

 (ee)    No “forward-looking statement” (within the
meaning of Section 27A of the Securities Act or Section 21E of the Exchange Act) included or incorporated by reference in the SEC Reports has been made or reaffirmed without a reasonable basis or has been disclosed other than in good
faith. 
 (ff)    Nothing has come to the attention of the Company that has caused the Company to believe that
the statistical and market-related data included or incorporated by reference in the SEC Reports is not based on or derived from sources that are reliable and accurate in all material respects. 

(gg)    There is and has been no failure on the part of the Company or, to the knowledge of the Company, any of the
Company’s directors or officers, in their capacities as such, to comply with any applicable provision of the Sarbanes-Oxley Act of 2002, as amended and the rules and regulations promulgated in connection therewith, including Section 402
related to loans and Sections 302 and 906 related to certifications. 
 (hh)    Neither the Company nor its
Subsidiaries has taken, directly or indirectly, any action designed to or that could reasonably be expected to cause or result in, any stabilization or manipulation of the price of the Shares. 

(ii)    Neither the Company nor its Subsidiaries nor any director, officer or employee of the Company or its
Subsidiaries nor, to the knowledge of the Company, any agent, employee or other person associated with or acting on behalf of the Company or any of its Subsidiaries have (i) used any corporate funds for any unlawful contribution, gift,
entertainment or other unlawful expense relating to political activity; (ii) made or taken an act in furtherance of an offer, promise or authorization of any direct or indirect unlawful payment or benefit to any foreign or domestic government
official or employee, including of any government-owned or controlled entity or of a public international organization, or any person acting in an official capacity for or on behalf of any of the foregoing, or any political party or party official
or candidate for political office; (iii) violated or is in violation of any provision of the Foreign Corrupt Practices Act of 1977, as amended, or any applicable law or regulation implementing the OECD Convention on Combating Bribery of Foreign
Public Officials in International Business Transactions, or committed an offence under the Bribery Act 2010 of the United Kingdom or any other applicable anti-bribery or anti-corruption law; or (iv) made, offered, agreed, requested or taken an
act in furtherance of any unlawful bribe or other unlawful benefit, including, without limitation, any rebate, payoff, influence payment, kickback or other unlawful or improper payment or benefit. The Company and its Subsidiaries have instituted,
maintain and enforce, and will continue to maintain and enforce policies and procedures designed to promote and ensure compliance with all applicable anti-bribery and anti-corruption laws. 

(jj)    The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance
with applicable financial recordkeeping and reporting requirements, including those of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the applicable money laundering statutes of all jurisdictions where the Company or its
Subsidiaries conduct business, the rules and regulations thereunder and any related or similar rules, regulations or guidelines issued, administered or enforced by any governmental agency (collectively, the “Anti-Money Laundering Laws”)
and no action, suit or proceeding by or before 

  
 12 

 
any court or governmental agency, authority or body or any arbitrator involving the Company or its Subsidiaries with respect to the Anti-Money Laundering Laws is pending or, to the knowledge of
the Company, threatened. 
 (kk)    Neither the Company nor its Subsidiaries, directors, officers, or employees,
nor, to the knowledge of the Company, any agent, affiliate or other person associated with or acting on behalf of the Company or its Subsidiaries is currently the subject or the target of any sanctions administered or enforced by the U.S.
government, (including, without limitation, the Office of Foreign Assets Control of the U.S. Department of the Treasury or the U.S. Department of State and including, without limitation, the designation as a “specially designated national”
or “blocked person”), the United Nations Security Council, the European Union, Her Majesty’s Treasury or other relevant sanctions authority (collectively, “Sanctions”), nor is the Company or its Subsidiaries
located, organized or resident in a country or territory that is the subject or target of Sanctions, including, without limitation, Crimea, Cuba, Iran, North Korea and Syria (each, a “Sanctioned Country”); and the Company
will not directly or indirectly use the proceeds of the offering of the Shares hereunder, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other person or entity (i) to fund or facilitate
any activities of or business with any person that, at the time of such funding or facilitation, is the subject or target of Sanctions, (ii) to fund or facilitate any activities of or business in any Sanctioned Country or (iii) in any
other manner that will result in a violation by any person (including any person participating in the transaction, whether as underwriter, advisor, investor or otherwise) of Sanctions. Since the Company’s inception, the Company and its
Subsidiaries have not knowingly engaged in and are not now knowingly engaged in any dealings or transactions with any person that at the time of the dealing or transaction is or was the subject or the target of Sanctions or with any Sanctioned
Country. 
 (ll)    No Subsidiary of the Company is currently prohibited, directly or indirectly, under any
agreement or other instrument to which it is a party or is subject, from paying any dividends to the Company, from making any other distribution on such subsidiary’s capital stock or similar ownership interest, from repaying to the Company any
loans or advances to such subsidiary from the Company or from transferring any of such subsidiary’s properties or assets to the Company or any other subsidiary of the Company. 

(mm)    (i) Except as described in the SEC Reports, the preclinical studies and clinical trials conducted by or, to
the knowledge of the Company, on behalf of or sponsored by the Company or its Subsidiaries, or in which the Company or its Subsidiaries have participated, that are described in the SEC Reports, or the results of which are referred to in the SEC
Reports, as applicable, were, and if still pending are, being conducted in all material respects in accordance with standard medical and scientific research standards and procedures for products or product candidates comparable to those being
developed by the Company and all applicable statutes and all applicable rules and regulations of the U.S. Food and Drug Administration and comparable regulatory agencies outside of the United States to which they are subject, including the European
Medicines Agency (collectively, the “Regulatory Authorities”), and applicable Good Clinical Practice and Good Laboratory Practice requirements; (ii) the descriptions in the SEC Reports of the results of such studies and
trials are accurate and complete descriptions in all material respects and fairly present the data derived therefrom; (iii) the Company has no knowledge of any other studies or trials not described in the SEC Reports, the results of which are
inconsistent with or call 

  
 13 

 
into question the results described or referred to in the SEC Reports; (iv) the Company and its Subsidiaries have operated at all times and are currently in compliance in all respects with
all applicable statutes, rules and regulations of the Regulatory Authorities, except where such non-compliance would not, individually or in the aggregate, have a Material Adverse Effect; and (v) neither
the Company nor its Subsidiaries have received any written notices, correspondence or other communications from the Regulatory Authorities or any other governmental agency requiring or threatening the termination, material modification or suspension
of any preclinical studies or clinical trials that are described in the SEC Reports or the results of which are referred to in the SEC Reports, other than ordinary course communications with respect to modifications in connection with the design and
implementation of such studies or trials, and, to the Company’s knowledge, there are no reasonable grounds for the same. 

(nn)    The Company has not failed to file with the Regulatory Authorities any required filing, declaration,
listing, registration, report or submission with respect to the Company’s product candidates that are described or referred to in the SEC Filings; all such filings, declarations, listings, registrations, reports or submissions, as applicable,
were in material compliance with applicable laws when filed; and no material deficiencies regarding compliance with applicable law have been asserted by any applicable regulatory authority with respect to any such filings, declarations, listings,
registrations, reports or submissions. 
 (oo)    The Company has not received any notice from the Nasdaq Global
Market regarding the delisting of the Common Stock. The Company is in material compliance with all listing and maintenance requirements of Nasdaq on the date hereof. 

(pp)    Assuming the accuracy of the Purchasers’ representations and warranties set forth in Section
3.2 of this Agreement, no registration under the Securities Act is required for the offer and sale of the Shares by the Company to the Purchasers hereunder. The issuance and sale of the Shares hereunder does not contravene the rules and
regulations of Nasdaq. 
 3.2    Representations, Warranties and Covenants of the Purchasers. Each
Purchaser, for itself and for no other Purchaser, hereby represents, warrants and covenants to the Company as of the Closing Date: 

(a)    Such Purchaser has all requisite legal and corporate or other power and capacity and has taken all requisite
corporate or other action to execute and deliver this Agreement, to purchase the Shares and to carry out and perform all of its obligations under this Agreement; and this Agreement constitutes the legal, valid and binding obligation of such
Purchaser, enforceable against such Purchaser in accordance with its terms, except (i) as limited by applicable bankruptcy, insolvency, reorganization or similar laws relating to or affecting the enforcement of creditors’ rights generally
and (ii) as limited by equitable principles generally. 
 (b)    At the time such Purchaser was offered the
Shares, it was, and as of the date hereof it is, (i) either: (A) an “accredited investor” as defined in Rule 501(a)(1), (a)(2), (a)(3), (a)(7) or (a)(8) under the Securities Act, or (B) a “qualified institutional buyer”
as defined in Rule 144A(a) under the Securities Act, (ii) an Institutional Account as defined in Financial Industry Regulatory Authority Rule 4512(c), and (iii) a sophisticated institutional investor, experienced in investing in private
equity transactions and capable of evaluating investment risks independently, both in general and with regard to all transactions and investment strategies involving a security 

  
 14 

 
or securities, including such Purchaser’s participation in the transactions contemplated by this Agreement. Such Purchaser has determined based on its own independent review and such
professional advice as it deems appropriate that its purchase of the Shares and participation in the transactions contemplated by this Agreement (i) are fully consistent with its financial needs, objectives and condition, (ii) comply and
are fully consistent with all investment policies, guidelines and other restrictions applicable to it, (iii) have been duly authorized and approved by all necessary action, (iv) do not and will not violate or constitute a default under its
charter, by-laws or other constituent document or under any law, rule, regulation, agreement or other obligation by which it is bound and (v) are a fit, proper and suitable investment for such Purchaser,
notwithstanding the substantial risks inherent in investing in or holding the Shares. Such Purchaser is able to bear the substantial risks associated with its purchase of the Shares, including but not limited to loss of its entire investment
therein. 
 (c)    Such Purchaser has (i) received, reviewed and understood the offering materials made
available to it in connection with the transactions contemplated by this Agreement, (ii) had the opportunity to ask questions of and receive answers from the Company directly and (iii) conducted and completed its own independent due
diligence with respect to the transactions contemplated by this Agreement. Based on such information as such Purchaser has deemed appropriate, such Purchaser has independently made its own analysis and decision to purchase the Shares. Except for the
representations, warranties and agreements of the Company expressly set forth in this Agreement, such Purchaser is relying exclusively on its own sources of information, investment analysis and due diligence (including professional advice it deems
appropriate) with respect to the transactions contemplated by this Agreement, the Shares and the business, condition (financial and otherwise), management, operations, properties and prospects of the Company, including but not limited to all
business, legal, regulatory, accounting, credit and tax matters. 
 (d)    Such Purchaser is acquiring its entire
beneficial ownership interest in the Shares for its own account for investment purposes only and not with a view to any distribution of the Share in any manner that would violate the securities laws of the United States or any other jurisdiction.

 (e)    Such Purchaser understands that the Shares are being offered and sold to it in reliance on specific
exemptions from the registration requirements of United States federal and state securities laws and that the Company is relying in part upon the truth and accuracy of, and such Purchaser’s compliance with, the representations, warranties,
agreements, acknowledgements and understandings of such Purchaser set forth herein in order to determine the availability of such exemptions and the eligibility of such Purchaser to acquire the Shares. Such Purchaser further acknowledges and
understands that the Shares may not be resold or otherwise transferred except in a transaction registered under the Securities Act or unless an exemption from such registration is available. 

(f)    Dispositions. 

(i)    Such Purchaser will not, prior to the effectiveness of the Resale Registration Statement, if then prohibited
by law or regulation other than pursuant to an available exemption under the Securities Act, sell, offer to sell, solicit offers to buy, dispose of, loan, pledge or grant any right with respect to the Shares. 

  
 15 

 (ii)    Such Purchaser has not directly or indirectly, nor has
any person acting on behalf of or pursuant to any understanding with such Purchaser, engaged in any purchases or sales of the Company’s securities (including, without limitation, any Short Sales involving the Company’s securities) since
the time that such Purchaser was first contacted by the Company or any other person regarding the transactions contemplated hereby. Such Purchaser covenants that neither it nor any person acting on its behalf or pursuant to any understanding with it
will engage in any purchases or sales of the Company’s securities (including, without limitation, any Short Sales involving the Company’s securities) prior to the time that the transactions contemplated by this Agreement are publicly
disclosed. 
 (g)    Such Purchaser has independently evaluated the merits of its decision to purchase Shares
pursuant to this Agreement. Such Purchaser understands that nothing in this Agreement or any other materials presented to such Purchaser in connection with the purchase and sale of the Shares constitutes legal, tax or investment advice. 

(h)    Such Purchaser will hold in confidence all information concerning this Agreement and the sale and issuance
of the Shares until the Company has made a public announcement concerning this Agreement and the sale and issuance of the Shares, which shall be made promptly following the execution and delivery hereof. 

(i)    Purchaser understands that no United States federal or state agency or any other government or governmental
agency has passed upon or made any recommendation or endorsement of the Shares. 
 (j)    Immediately prior to
the Closing, such Purchaser, together with its affiliates and any other persons acting as a group together with such Purchaser and any of its affiliates, beneficially owned the number of shares of Common Stock set forth on such Purchaser’s
signature page attached hereto (as such ownership is calculated pursuant to the rules of Nasdaq). 
 (k)    If
such Purchaser is not a United States person (as defined by Section 7701(a)(30) of the Code), such Purchaser hereby represents that it has satisfied itself as to the full observance of the laws of its jurisdiction in connection with any
invitation to subscribe for the Shares or any use of this Agreement, including (a) the legal requirements within its jurisdiction for the purchase of the Shares, (b) any foreign exchange restrictions applicable to such purchase or
acquisition, (c) any government or other consents that may need to be obtained, and (d) the income tax and other tax consequences, if any, that may be relevant to the purchase, holding, redemption, sale or transfer of the Shares. Such
Purchaser’s subscription and payment for and continued beneficial ownership of the Shares will not violate any applicable securities or other laws of such Purchaser’s jurisdiction. 

  
 16 

	4.	 REGISTRATION RIGHTS 

4.1    Definitions. For the purpose of this Section 4: 

(a)    the term “Resale Registration Statement” shall mean any registration statement
required to be filed by Section 4.2 below, and shall include any preliminary prospectus, final prospectus, exhibit or amendment included in or relating to such registration statements; and 

(b)    the term “Registrable Shares” means the Shares; provided, however,
that a security shall cease to be a Registrable Share upon the earliest to occur of the following: (i) a Resale Registration Statement registering such security under the Securities Act has been declared or becomes effective and such security
has been sold or otherwise transferred by the holder thereof pursuant to and in a manner contemplated by such effective Resale Registration Statement, (ii) such security is sold pursuant to Rule 144 under circumstances in which any legend borne
by such security relating to restrictions on transferability thereof, under the Securities Act or otherwise, is removed by the Company, (iii) such security is eligible to be sold pursuant to Rule 144 without condition or restriction, including
without any limitation as to volume of sales, and without the Holder complying with any method of sale requirements or notice requirements under Rule 144, or (iv) such security shall cease to be outstanding following its issuance. 

4.2    Registration Procedures and Expenses. The Company shall: 

(a)    file a Resale Registration Statement (the “Mandatory Registration Statement”) with
the Commission on or before the date forty-five (45) days following the Closing Date (the “Filing Date”) to register all of the Registrable Shares on Form S-3 under the Securities
Act (providing for shelf registration of such Registrable Shares under Commission Rule 415). In the event that Form S-3 is not available for the registration of the Registrable Shares, the Company shall
register the resale of the Registrable Shares on such other form as is available to the Company; 

(b)    use its reasonable best efforts to cause such Mandatory Registration Statement to be
declared effective as soon as practicable and in any event within sixty (60) days following the Filing Date (the foregoing or the applicable date set forth in Section 4.2(i), the “Effectiveness
Deadline”), such efforts to include, without limiting the generality of the foregoing, preparing and filing with the Commission any financial statements or other information that is required to be filed prior to the effectiveness of
such Mandatory Registration Statement; 
 (c)    notwithstanding anything contained in this Agreement to the
contrary, in the event that the Commission limits the amount of Registrable Shares or otherwise requires a reduction in the number of Registrable Shares that may be included and sold by the Purchasers in the Mandatory Registration Statement (in each
case, subject to Section 4.4), then the Company shall prepare and file (i) within ten (10) Trading Days of the first date or time that such excluded Registrable Shares may then be included in a Resale Registration Statement if
the Commission shall have notified the Company that certain Registrable Shares were not eligible for inclusion in the Resale Registration Statement or (ii) in all other cases, within twenty (20) days following the date that the Company
becomes aware that such additional Resale Registration Statement is required (the “Additional Filing Date”), a Resale Registration Statement (any such Resale Registration Statement registering such excluded
Registrable Shares, an “Additional Registration 

  
 17 

 
Statement” and, together with the Mandatory Registration Statement, a “Resale Registration Statement”) to register any Registrable Shares
that have been excluded (or, if applicable, the maximum number of such excluded Registrable Shares that the Company is permitted to register for resale on such Additional Registration Statement consistent with Commission guidance), if any, from
being registered on the Mandatory Registration Statement; 
 (d)    (i) not less than two (2) Trading Days
prior to the filing of a Registration Statement or any related prospectus or any amendment or supplement thereto, furnish via email to those Purchasers who have supplied the Company with email addresses copies of all such documents proposed to be
filed, which documents (other than any document that is incorporated or deemed to be incorporated by reference therein) will be subject to the review of such Purchasers and (ii) reflect in each such document when so filed with the Commission
such comments regarding the Purchasers and the plan of distribution as the Purchasers may reasonably and promptly propose no later than two (2) Trading Days after the Purchasers have been so furnished with copies of such documents as aforesaid;

 (e)    use its reasonable best efforts to cause any such Additional Registration Statement to be declared
effective as promptly as practicable following the Additional Filing Date, such efforts to include, without limiting the generality of the foregoing, preparing and filing with the Commission any financial statements or other information that is
required to be filed prior to the effectiveness of any such Additional Registration Statement; 
 (f)    prepare
and file with the Commission such amendments and supplements to such Resale Registration Statements and the prospectus used in connection therewith as may be necessary to keep such Resale Registration Statements continuously effective and free from
any material misstatement or omission to state a material fact therein until termination of such obligation as provided in Section 4.7 below, subject to the Company’s right to suspend pursuant to
Section 4.6; 
 (g)    furnish to the Purchasers such number of copies of prospectuses
in conformity with the requirements of the Securities Act and such other documents as the Purchasers may reasonably request, in order to facilitate the public sale or other disposition of all or any of the Registrable Shares by the Purchasers; 

(h)    file such documents as may be required of the Company for normal securities law clearance for the resale of
the Registrable Shares in such states of the United States as may be reasonably requested by the Purchasers and use its commercially reasonable efforts to maintain such blue sky qualifications during the period the Company is required to maintain
effectiveness of the Resale Registration Statements; provided, however, that the Company shall not be required in connection with this Section 4.2(h) to qualify as a foreign corporation or execute a general
consent to service of process in any jurisdiction in which it is not now so qualified or has not so consented; 

(i)    upon notification by the Commission that the Resale Registration Statement will not be reviewed or is not
subject to further review by the Commission, the Company shall within three (3) Trading Days following the date of such notification request acceleration of such Resale Registration Statement (with the requested effectiveness date to be not
more than two (2) Trading Days later); 

  
 18 

 (j)    upon notification by the Commission that that the Resale
Registration Statement has been declared effective by the Commission, the Company shall file the final prospectus under Rule 424 of the Securities Act (“Rule 424”) within the applicable time period prescribed by Rule 424;

 (k)    advise the Purchasers promptly (and in any event within two (2) Trading Days thereof): 

(i)    of the effectiveness of the Resale Registration Statement or any post-effective amendments thereto; 

(ii)    of any request by the Commission for amendments to the Resale Registration Statement or amendments to the
prospectus or for additional information relating thereto; 
 (iii)    of the issuance by the Commission of any
stop order suspending the effectiveness of the Resale Registration Statement under the Securities Act or of the suspension by any state securities commission of the qualification of the Registrable Shares for offering or sale in any jurisdiction, or
the initiation of any proceeding for any of the preceding purposes; and 
 (iv)    of the existence of any fact
and the happening of any event that makes any statement of a material fact made in the Resale Registration Statement, the prospectus and amendment or supplement thereto, or any document incorporated by reference therein, untrue, or that requires the
making of any additions to or changes in the Resale Registration Statement or the prospectus in order to make the statements therein not misleading; 

(l)    cause all Registrable Shares to be listed on each securities exchange, if any, on which equity securities by
the Company are then listed; and 
 (m)    bear all expenses in connection with the procedures in paragraphs
(a) through (l) of this Section 4.2 and the registration of the Registrable Shares on such Resale Registration Statement and the satisfaction of the blue sky laws of any applicable states. 

4.3    Selling Stockholder Questionnaire. Each Purchaser agrees to furnish to the Company a completed
Selling Shareholder Questionnaire, in the form provided by the Company (to be a reasonably customary form), not more than five (5) Trading Days following the date such form is provided to such Purchaser. Each Purchaser further agrees that it
shall not be entitled to be named as a selling securityholder in the Resale Registration Statement or use the prospectus filed in connection therewith for offers and resales of Registrable Securities at any time, unless such Purchaser has returned
to the Company a completed and signed Selling Shareholder Questionnaire and any further information reasonably requested by the Company. Each Purchaser acknowledges and agrees that the information in the Selling Shareholder Questionnaire or request
for further information as described in this Section 4.3 will be used by the Company in the preparation of the Resale Registration Statement and hereby consents to the inclusion of such information in the Resale
Registration Statement. 
 4.4    Rule 415; Cutback. If at any time the staff of the Commission
(“Staff”) takes the position that the offering of some or all of the Registrable Shares in a Registration Statement is not 

  
 19 

 
eligible to be made on a delayed or continuous basis under the provisions of Rule 415 under the Securities Act or requires any Purchaser to be named as an “underwriter,” the Company
shall (in consultation with legal counsel to Deep Track Capital, L.P.) use its reasonable best efforts to persuade the Commission that the offering contemplated by the Registration Statement is a valid secondary offering and not an offering “by
or on behalf of the issuer” as defined in Rule 415 and that none of the Purchasers is an “underwriter.” In the event that, despite the Company’s reasonable best efforts and compliance with the terms of this
Section 4.4, the Staff refuses to alter its position, the Company shall (i) remove from the Registration Statement such portion of the Registrable Shares (the “Cut Back Shares”) and/or
(ii) agree to such restrictions and limitations on the registration and resale of the Registrable Shares as the Staff may require to assure the Company’s compliance with the requirements of Rule 415 (collectively, the
“SEC Restrictions”); provided, however, that the Company shall not agree to name any Purchaser as an “underwriter” in such Registration Statement without the prior written consent of such
Purchaser. Any cutback imposed on the Purchasers pursuant to this Section 4.4 shall be allocated among the Purchasers on a pro rata basis, unless the SEC Restrictions otherwise require or provide or the Purchasers holding a
majority of the Registrable Shares otherwise agree. No liquidated damages shall accrue as to any Cut Back Shares until such date as the Company is able to effect the registration of such Cut Back Shares in accordance with any SEC Restrictions (such
date, the “Restriction Termination Date” of such Cut Back Shares). From and after the Restriction Termination Date applicable to any Cut Back Shares, all of the provisions of this Section 4 shall
again be applicable to such Cut Back Shares; provided, however, that (x) the Filing Deadline for the Registration Statement including such Cut Back Shares shall be ten (10) Trading Days after such Restriction Termination
Date, and (y) the Effectiveness Deadline with respect to such Cut Back Shares shall be the 90th day immediately after the Restriction Termination Date or the 120th day if the Staff reviews such Registration Statement (but in any event no later than three Trading Days from the Staff indicating it has no further comments on such Registration Statement). 

4.5    Indemnification. 

(a)    The Company agrees to indemnify and hold harmless each Purchaser and its affiliates, partners, members,
officers, directors, agents and representatives, and each person, if any, who controls such Purchaser within the meaning of the Securities Act or the Exchange Act (each, a “Purchaser Party” and collectively the
“Purchaser Parties”), from and against any losses, claims, damages or liabilities (collectively, “Losses”) to which they may become subject (under the Securities Act or otherwise) insofar as such
Losses (or actions or proceedings in respect thereof) arise out of, or are based upon, any material breach of this Agreement by the Company or any untrue statement or alleged untrue statement of a material fact contained in the Resale Registration
Statement or any omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading or arise out of any
material failure by the Company to fulfill any undertaking included in the Resale Registration Statement and the Company will, as incurred, reimburse the Purchaser Parties for any legal or other documented expenses reasonably incurred in
investigating, defending or preparing to defend any such action, proceeding or claim; provided, however, that the Company shall not be liable to any Purchaser in any such case to the extent that such Loss arises out of,
or is based upon: (i) an untrue statement or omission or alleged untrue statement or omission made in such Resale Registration Statement in reliance upon and in conformity with written information furnished to the Company by or on behalf of
such Purchaser 

  
 20 

 
specifically for use in preparation of the Resale Registration Statement; or (ii) any material breach of this Agreement by such Purchaser;
provided further, however, that the Company shall not be liable to any Purchaser Party to the extent that any such Loss is caused by an untrue statement or omission or alleged untrue statement or omission made in any
preliminary prospectus if either (i) (A) such Purchaser failed to send or deliver a copy of the final prospectus with or prior to, or such Purchaser failed to confirm that a final prospectus was deemed to be delivered prior to (in accordance
with Rule 172 of the Securities Act), the delivery of written confirmation of the sale by such Purchaser to the person asserting the claim from which such Loss resulted and (B) the final prospectus corrected such untrue statement or omission,
(ii) (X) such untrue statement or omission is corrected in an amendment or supplement to the prospectus and (Y) having previously been furnished by or on behalf of the Company with copies of the prospectus as so amended or supplemented or
notified by the Company that such amended or supplemented prospectus has been filed with the Commission, in accordance with Rule 172 of the Securities Act, such Purchaser thereafter fails to deliver such prospectus as so amended or supplemented,
with or prior to or a Purchaser fails to confirm that the prospectus as so amended or supplemented was deemed to be delivered prior to (in accordance with Rule 172 of the Securities Act), the delivery of written confirmation of the sale by such
Purchaser to the person asserting the claim from which such Loss resulted or (iii) such Purchaser sold Registrable Shares in violation of such Purchasers’ covenants contained in Section 3.2 of this Agreement. 

(b)    Each Purchaser agrees, severally and not jointly, to indemnify and hold harmless the Company and its
officers, directors, affiliates, agents and representatives and each person, if any, who controls the Company within the meaning of the Securities Act or the Exchange Act (each a “Company Party” and collectively
the “Company Parties”), from and against any Losses to which the Company Parties may become subject (under the Securities Act or otherwise), insofar as such Losses (or actions or proceedings in respect thereof)
arise out of, or are based upon, any material breach of this Agreement by such Purchaser or untrue statement or alleged untrue statement of a material fact contained in the Resale Registration Statement (or any omission or alleged omission to state
therein a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading in each case, on the effective date thereof), if, and only to the extent,
such untrue statement or omission or alleged untrue statement or omission was made in reliance upon and in conformity with written information furnished by or on behalf of such Purchaser specifically for use in preparation of the Resale Registration
Statement, and each Purchaser, severally and not jointly, will reimburse each Company Party for any legal or other expenses reasonably incurred in investigating, defending or preparing to defend any such action, proceeding or claim;
provided, however, that in no event shall any indemnity under this Section 4.5(b) be greater in amount than the dollar amount of the net proceeds received by such Purchaser upon its sale of the
Registrable Shares included in the Registration Statement giving rise to such indemnification obligation. 

(c)    Promptly after receipt by any indemnified person of a notice of a claim or the beginning of any action in
respect of which indemnity is to be sought against an indemnifying person pursuant to this Section 4.5, such indemnified person shall notify the indemnifying person in writing of such claim or of the commencement of such
action, and, subject to the provisions hereinafter stated, in case any such action shall be brought against an indemnified person and such indemnifying person shall have been notified thereof, such indemnifying person shall be entitled to
participate therein, and, to the extent that it shall wish, to assume the defense thereof, with 

  
 21 

 
counsel reasonably satisfactory to such indemnified person. After notice from the indemnifying person to such indemnified person of its election to assume the defense thereof, such indemnifying
person shall not be liable to such indemnified person for any legal expenses subsequently incurred by such indemnified person in connection with the defense thereof; provided, however, that if there exists or shall exist
a conflict of interest that would make it inappropriate in the reasonable judgment of the indemnified person for the same counsel to represent both the indemnified person and such indemnifying person or any affiliate or associate thereof, the
indemnified person shall be entitled to retain its own counsel at the expense of such indemnifying person; provided, further, that no indemnifying person shall be responsible for the fees and expense of more than one separate counsel
for all indemnified parties. The indemnifying party shall not settle an action without the consent of the indemnified party, which consent shall not be unreasonably withheld. 

(d)    If after proper notice of a claim or the commencement of any action against the indemnified party, the
indemnifying party does not choose to participate, then the indemnified party shall assume the defense thereof and upon written notice by the indemnified party requesting advance payment of a stated amount for its reasonable defense costs and
expenses, the indemnifying party shall advance payment for such reasonable defense costs and expenses (the “Advance Indemnification Payment”) to the indemnified party. In the event that the indemnified party’s actual
defense costs and expenses exceed the amount of the Advance Indemnification Payment, then upon written request by the indemnified party, the indemnifying party shall reimburse the indemnified party for such difference; in the event that the Advance
Indemnification Payment exceeds the indemnified party’s actual costs and expenses, the indemnified party shall promptly remit payment of such difference to the indemnifying party. 

(e)    If the indemnification provided for in this Section 4.5 is held by a court of
competent jurisdiction to be unavailable to an indemnified party with respect to any Losses, the indemnifying party, in lieu of indemnifying such indemnified party thereunder, shall to the extent permitted by applicable law contribute to the amount
paid or payable by such indemnified party as a result of such Loss in such proportion as is appropriate to reflect the relative fault of the indemnifying party on the one hand and of the indemnified party on the other, as well as any other relevant
equitable considerations; provided, that in no event shall any contribution by an indemnifying party hereunder be greater in amount than the dollar amount of the proceeds received by such indemnifying party upon the sale of such Registrable
Shares. 
 4.6    Prospectus Suspension. Each Purchaser acknowledges that there may be times when the
Company must suspend the use of the prospectus forming a part of the Resale Registration Statement until such time as an amendment to the Resale Registration Statement has been filed by the Company and declared effective by the Commission, or until
such time as the Company has filed an appropriate report with the Commission pursuant to the Exchange Act. Each Purchaser hereby covenants that it will not sell any Registrable Shares pursuant to said prospectus during the period commencing at the
time at which the Company gives the Purchasers notice of the suspension of the use of said prospectus and ending at the time the Company gives the Purchasers notice that the Purchasers may thereafter effect sales pursuant to said prospectus;
provided, that such suspension periods may only be imposed by the Company for up to two periods of not more than thirty (30) consecutive days in any twelve (12) month period and that, in the good faith judgment of the Company’s
board of directors, the Company would, in the absence of such delay or suspension hereunder, be required under state or federal securities laws to disclose any 

  
 22 

 
corporate development, a potentially significant transaction or event involving the Company, or any negotiations, discussions, or proposals directly relating thereto, in either case the
disclosure of which would reasonably be expected to have a material adverse effect upon the Company or its stockholders. 

4.7    Termination of Obligations. The obligations of the Company pursuant to
Section 4.2 hereof shall cease and terminate, with respect to any Registrable Shares, upon the earliest to occur of (a) such time such Registrable Shares have been resold, (b) such time as such Registrable Shares
no longer remain Registrable Shares pursuant to Section 4.1(b) hereof or (c) two years from the effective date of the Resale Registration Statement. 

4.8    Reporting Requirements. 

(a)    With a view to making available the benefits of certain rules and regulations of the Commission that may at
any time permit the sale of the Shares to the public without registration or pursuant to a registration statement on Form S-3, for a period of two years from the Closing Date, the Company agrees to use its
reasonable best efforts to: 
 (i)    make and keep public information available, as those terms are understood
and defined in Rule 144; 
 (ii)    file with the Commission in a timely manner all reports and other documents
required of the Company under the Securities Act and the Exchange Act; and 
 (iii)    so long as a Purchaser
owns Registrable Shares, to furnish to such Purchaser upon request (A) a written statement by the Company as to whether it is in compliance with the reporting requirements of Rule 144, the Securities Act and the Exchange Act, or whether it is
qualified as a registrant whose securities may be resold pursuant to Commission Form S-3, (B) a copy of the most recent annual or quarterly report of the Company and such other reports and documents so filed
by the Company and (C) such other information as may be reasonably requested to permit the Purchaser to sell such securities pursuant to Rule 144. 

4.9    Blue Sky. The Company shall obtain and maintain all necessary blue sky law permits and
qualifications, or secured exemptions therefrom, required by any state for the offer and sale of Registrable Shares. 
  

	5.	 OTHER AGREEMENTS OF THE PARTIES 

5.1    Integration. Except as contemplated by the terms of this Agreement, the Company shall not sell, offer
for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in Section 2 of the Securities Act) that would be integrated with the offer or sale of the Shares such that the rules of Nasdaq would require
shareholder approval of this transaction prior to the closing of such other transaction unless shareholder approval is obtained before the closing of such subsequent transaction. 

5.2    Securities Laws Disclosure; Publicity. The Company shall: (a) promptly following the execution
and delivery hereof, issue a press release disclosing the material terms of the transactions contemplated hereby (the “Press Release”), and (b) by 5:30 p.m. (New York City

  
 23 

 
time) on the fourth (4th) Trading Day following the date hereof, file a Current Report on Form 8-K
disclosing the material terms of the transactions contemplated hereby. Subject to the foregoing, neither the Company nor any Purchaser shall issue any press releases or any other public statements with respect to the transactions contemplated hereby
except as may be reviewed and approved by the Company; provided, however, that the Company shall be entitled, without the prior approval of any Purchaser, to make any press release or other public disclosure with respect to the
transactions contemplated hereby, provided, further, however, that the Company shall not publicly disclose the name of any Purchaser or an affiliate of any Purchaser except as otherwise required by applicable law and regulations
or as agreed to by the applicable Purchaser. 
 5.3    Legend. 

(a)    Each Purchaser understands that the Shares shall bear a restrictive legend in substantially the following
form (and a stop transfer order may be placed against transfer of the certificates for the Shares): 
 “THE SECURITIES REPRESENTED BY
THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES OR IN ANY OTHER JURISDICTION. THE SECURITIES REPRESENTED HEREBY MAY NOT BE OFFERED, SOLD OR TRANSFERRED
IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER APPLICABLE SECURITIES LAWS UNLESS OFFERED, SOLD OR TRANSFERRED PURSUANT TO AN AVAILABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THOSE LAWS.” 

(b)    The Company shall, at its sole expense, upon appropriate notice from any Purchaser stating that Registrable
Shares have been sold pursuant to an effective Registration Statement, timely prepare and deliver certificates or book-entry shares representing the Shares to be delivered to a transferee pursuant to the Registration Statement, which certificates or
book-entry shares shall be free of any restrictive legends and in such denominations and registered in such names as such Purchaser may request. Further, the Company shall, at its sole expense, cause its legal counsel or other counsel satisfactory
to the transfer agent: (i) while the Registration Statement is effective, to issue to the transfer agent a “blanket” legal opinion to allow (A) the legend on the Shares to be removed, or (B) sales without restriction
pursuant to the effective Registration Statement, and (ii) provide all other opinions as may reasonably be required by the transfer agent in connection with the removal of legends. A Purchaser may request that the Company remove, and the
Company agrees to authorize the removal of, any legend from such Shares, following the delivery by a Purchaser to the Company or the Company’s transfer agent of a legended certificate representing such Shares: (i) following any sale of
such Shares pursuant to Rule 144, (ii) if such Shares are eligible for sale under Rule 144(b)(1), or (iii) following the time that the Registration Statement is declared effective. If a legend removal request is made pursuant to the foregoing,
the Company will, no later than three (3) Trading Days following the delivery by a Purchaser to the Company or the Company’s transfer agent of a legended certificate representing such Shares (or a request for legend removal, in the case of
Shares issued in book-entry form), deliver or cause to be delivered to such Purchaser a certificate representing such Shares that is free 

  
 24 

 
from all restrictive legends or an equivalent book-entry position, as requested by the Purchaser. Certificates for Shares free from all restrictive legends may be transmitted by the
Company’s transfer agent to the Purchasers by crediting the account of the Purchaser’s prime broker with the Depository Trust Company (“DTC”) as directed by such Purchaser. The Company warrants that the Shares shall
otherwise be freely transferable on the books and records of the Company as and to the extent provided in this Agreement. If a Purchaser effects a transfer of the Shares in accordance with Section 5.3(b), the Company shall
permit the transfer and shall promptly instruct its transfer agent to issue one or more certificates or credit shares to the applicable balance accounts at DTC in such name and in such denominations as specified by such Purchaser to effect such
transfer. Such Purchaser hereby agrees that the removal of the restrictive legend pursuant to this Section 5.3(b) is predicated upon the Company’s reliance that such Purchaser will sell any such Shares pursuant to
either the registration requirements of the Securities Act, including any applicable prospectus delivery requirements, or an exemption therefrom. 

5.4    Non-Public Information. Except with respect to the material
terms and conditions of the transactions contemplated by the Transaction Documents, the Company covenants and agrees that neither it, nor any of its officers, directors, employees or agents acting on its behalf, will provide any Purchaser or its
agents or counsel with any information that constitutes, or the Company reasonably believes constitutes, material non-public information, unless prior thereto such Purchaser shall have consented to the receipt
of such information and agreed with the Company to keep such information confidential. 
 5.5    Reservation
of Common Stock. As of the date hereof, the Company has reserved, and the Company shall continue to reserve and keep available at all times, free of preemptive rights, a sufficient number of shares of Common Stock for the purpose of enabling the
Company to issue the Shares. 
 5.6    Nasdaq Listing. The Company shall prepare and file with Nasdaq an
additional shares listing application covering all of the Shares. 
 5.7    Preservation of Rights. Prior
to the date the Mandatory Registration Statement is declared effective by the Commission, the Company shall not (a) grant any registration rights to third parties which are more favorable than or inconsistent with the rights granted hereunder, or
(b) enter into any agreement, take any action, or permit any change to occur, with respect to its securities that violates or subordinates the rights expressly granted to the holders of Registrable Shares in this Agreement. 

5.8    Equal Treatment of Purchasers. No Purchaser has received terms in respect of its purchase of the
Shares that are more favorable than those of any other Purchaser, other than (i) the reimbursement of legal and due diligence expenses set forth in Section 6.2 hereof, (ii) terms particular to the regulatory
requirements of such Purchaser or its affiliates or related funds or (iii) terms concerning the publicity policies of such Purchaser. 
  

	6.	 MISCELLANEOUS 

6.1    Termination. This Agreement may be terminated by any Purchaser, as to such Purchaser’s
obligations hereunder only and without any effect whatsoever on the obligations between the Company and the other Purchasers, by written notice to the other parties, if the Closing 

  
 25 

 
has not been consummated within ten (10) calendar days from the Effective Date through no fault of such Purchaser; provided, however, that no such termination will affect the
right of any party to sue for any breach by the other party (or parties). 
 6.2    Fees and Expenses.
Except as expressly set forth in the Transaction Documents to the contrary, each party shall pay the fees and expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the
negotiation, preparation, execution, delivery and performance of this Agreement, provided, however, that, if the Closing occurs, the Company shall pay the reasonable and documented legal and due diligence expenses of (i) Deep
Track Capital, L.P. up to an aggregate of $100,000 and (ii) TCG Crossover LLC up to an aggregate of $9,000. Notwithstanding the foregoing, the Company shall pay all transfer agent fees, stamp taxes and other taxes and duties levied in
connection with the delivery of any Shares to the Purchasers. 
 6.3    Entire Agreement. The Transaction
Documents, together with the exhibits and schedules thereto, contain the entire understanding of the parties with respect to the subject matter hereof and supersede all prior agreements and understandings, oral or written, with respect to such
subject matter, which the parties acknowledge have been merged into such documents, exhibits and schedules. 

6.4    Notices. Any and all notices or other communications or deliveries required or permitted to be
provided hereunder shall be in writing and shall be deemed given and effective upon actual receipt via mail, courier or confirmed email by the party to whom such notice is required to be given. The address for such notices and communications shall
be as set forth on the signature pages attached hereto. 
 6.5    Amendments; Waivers. No provision of
this Agreement may be waived or amended except in a written instrument signed, in the case of an amendment, by (a) the Company and (b) Purchasers holding at least a majority of the Shares sold (or, prior to the Closing, contemplated to be
sold) in the Closing and then-held by a Purchaser or, in the case of a waiver, by the party against whom enforcement of any such waived provision is sought; provided, that if any amendment, disproportionately and adversely impacts a Purchaser
(or group of Purchasers) in any material respect, the consent of such disproportionately impacted Purchaser (or group of Purchasers) shall also be required. No waiver of any default with respect to any provision, condition or requirement of this
Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of any party to exercise any right hereunder
in any manner impair the exercise of any such right. 
 6.6    Headings. The headings herein are for
convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any of the provisions hereof. 

6.7    Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties
and their permitted successors and assigns. The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent of each Purchaser (other than by merger). The Purchasers may not assign this Agreement or
any rights or obligations hereunder without the prior written consent of the Company (other than by merger). 

  
 26 

 6.8    Third-Party Beneficiaries. This Agreement is
intended for the benefit of the parties hereto, and their respective permitted successors and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other person, except as otherwise set forth in
Section 4.5(a). 
 6.9    Governing Law. All questions concerning the
construction, validity, enforcement and interpretation of the Transaction Documents shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law
thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a party hereto or its
respective affiliates, directors, officers, shareholders, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the State of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of
the state and federal courts sitting in the State of New York for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of any
of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is
improper or is an inconvenient venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or
certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof.
Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. If either party shall commence an action or proceeding to enforce any provisions of the Transaction Documents, then the
prevailing party in such action or proceeding shall be reimbursed by the other party for its reasonable attorneys’ fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding. 

6.10    Execution. This Agreement may be executed in two or more counterparts, all of which when taken
together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to each other party, it being understood that the parties need not sign the same counterpart.
Counterparts may be delivered via facsimile, electronic mail (including any electronic signature covered by the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act, the Electronic Signatures and Records Act or other applicable law,
e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. 

6.11    Severability. If any term, provision, covenant or restriction of this Agreement is held by a court
of competent jurisdiction to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force and effect and shall in no way be affected, impaired or
invalidated, and the parties hereto shall use their commercially reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision, covenant or restriction.
It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void or
unenforceable. 

  
 27 

 6.12    Rescission and Withdrawal Right. Notwithstanding
anything to the contrary contained in (and without limiting any similar provisions of) any of the other Transaction Documents, whenever any Purchaser exercises a right, election, demand or option under a Transaction Document and the Company does not
timely perform its related obligations within the periods therein provided, then such Purchaser may rescind or withdraw, in its sole discretion from time to time upon written notice to the Company, any relevant notice, demand or election in whole or
in part without prejudice to its future actions and rights. 
 6.13    Replacement of Shares. If any
certificate or instrument evidencing any Shares is mutilated, lost, stolen or destroyed, the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation), or in lieu of and
substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction and customary and reasonable indemnity or bond, if requested. The applicant for a new
certificate or instrument under such circumstances shall also pay any reasonable third-party costs (including customary indemnity) associated with the issuance of such replacement Shares. 

6.14    Remedies. The Company shall be entitled to exercise all rights provided herein or granted by law,
including recovery of damages, for any breach of the Transaction Documents. 
 6.15    Independent Nature of
Purchasers’ Obligations and Rights. The obligations of each Purchaser under any Transaction Document are several and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance
or non-performance of the obligations of any other Purchaser under any Transaction Document. Nothing contained herein or in any other Transaction Document, and no action taken by any Purchaser pursuant
thereto, shall be deemed to constitute the Purchasers as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Purchasers are in any way acting in concert or as a group with respect to such
obligations or the transactions contemplated by the Transaction Documents. Each Purchaser shall be entitled to independently protect and enforce its rights, including without limitation, the rights arising out of this Agreement or out of the other
Transaction Documents, and it shall not be necessary for any other Purchaser to be joined as an additional party in any proceeding for such purpose. 

  
 28 

 6.16    Construction. The parties agree that each of them
and/or their respective counsel has reviewed and had an opportunity to revise the Transaction Documents and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting party shall not be
employed in the interpretation of the Transaction Documents or any amendments hereto. 
 6.17    WAIVER OF
JURY TRIAL. IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY,
UNCONDITIONALLY, IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY. 
 [Remainder of page intentionally left blank.] 

  
 29 

 IN WITNESS WHEREOF, the
parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above. 

 

			
	MAGENTA THERAPEUTICS, INC.
	
	 /s/ Jason Gardner

	Name:	 	Jason Gardner
	Title:	 	President and Chief Executive Officer
	
	Address for Notice:
	
	Magenta Therapeutics, Inc.
	100 Technology Square
	Cambridge, Massachusetts, 02139
	Attn: Jason Gardner
	
	With a copy to (which shall not constitute notice):
	
	Goodwin Procter LLP
	100 Northern Avenue
	Boston, Massachusetts, 02210
	Attn: Mitchell S. Bloom
	          Gregg L. Katz
	          William D. Collins
	E-mail: mbloom@goodwinlaw.com
	             gkatz@goodwinlaw.com

            wcollins@goodwinlaw.com

  
 [Signature Page to
Securities Purchase Agreement] 

 EXHIBIT A 

CLOSING SCHEDULE 
  

									
	 Investor
	  	Shares of
Common Stock
to be Purchased	 	  	Purchase Price
for Common
Stock	 
		  				  			
		  				  			
		  				  			
		  				  			
		  				  			
		  				  			

  
 A-1EXHIBIT 10.2 ASSET PURCHASE AGREEMENT

  
 EXHIBIT 10.2
 

 ASSET PURCHASE AGREEMENT
 THIS ASSET PURCHASE AGREEMENT (the “APA”) is entered into effective as of the date of the last signature (the “Effective Date”), by and among ZEUUS, INC., a Nevada corporation (“Purchaser”), and ANDREI SELEZNEV, NIKOLAY ALEKSEEV, and ILIA ALEKSEEV, individuals residing in Montenegro and Russia (each, a “Seller,” and collectively, the “Sellers”). Purchaser and Sellers are each hereinafter referred to individually, as a “Party,” and collectively, as the “Parties.”
 Recitals
 A.
 Sellers have developed innovative wind turbine technology using the concentration of wind stream, which increases the efficacy of wind turbines in weak and medium winds (the “Wind Turbine Technology”). 
 B.
 Sellers desire to sell to Purchaser, and Purchaser desires to acquire from Sellers, all of the assets comprising the current version of the Wind Turbine Technology (which includes all Intellectual Property (defined below), code, other intangibles, and all related documentation associated with the Wind Turbine Technology). 
 C.
 The Parties desire to work together over the next two years to further develop the Wind Turbine Technology and implement, grow, commercialize, and protect the branding, marketing, and sales of the Wind Turbine Technology on the terms and conditions set forth in this APA. 
 Agreement
 NOW, THEREFORE, in consideration of the foregoing Recitals (which are incorporated herein by this reference), the respective representations, warranties, covenants, and agreements set forth in this APA, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged and confirmed, the Parties agree as follows:
 Article 1
 Definitions and Interpretation
 Section 1.01
 Defined Terms. When used herein, the following terms will have the meanings set forth below: 
 (a)
 “Acquired Assets” has the meaning specified in section 2.02.
 (b)
 “APA” means this Asset Purchase Agreement, including all schedules and exhibits hereto, as amended, modified, supplemented, restated, or renewed from time to time. 
 (c)
 “Applicable Law” means any domestic or foreign law, statute, regulation, rule, policy, guideline, or ordinance. 
 (d)
 “Authorizations” means franchises, tariffs, licenses, ordinances, certifications, approvals, authorizations, and permits. 
 (e)
 “Bill of Sale” has the meaning specified in section 2.02.
 (f)
 “Closing” has the meaning specified in subsection 2.08(b). 
 

 
 
 (g)
 “Closing Date” has the meaning specified in subsection 2.08(b). 
 (h)
 “Code” means the United States Internal Revenue Code of 1986, as amended, and the regulations promulgated thereunder.
 (i)
 “Confidential Information” has the meaning specified in subsection 8.03(d). 
 (j)
 “Effective Date” has the meaning specified in the preamble. 
 (k)
 “Effective Time” has the meaning specified in subsection 2.08(b). 
 (l)
 “Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder. 
 (m)
 “Excluded Assets” has the meaning specified in section 2.03.
 (n)
 “GAAP” means generally accepted accounting principles in the United States that are: (i) consistent with the principles promulgated or adopted by the Financial Accounting Standards Board and its predecessors and other recognized principle setting bodies, in effect from time to time; (ii) applied on a basis consistent with prior periods; and (iii) such that a certified public accountant would, insofar as the use of accounting principles is pertinent, be in a position to base an opinion as to financial statements in which such principles have been properly applied.
 (o)
 “Indemnified Party” has the meaning specified in section 9.02. 
 (p)
 “Indemnifying Party” has the meaning specified in section 9.02. 
 (q)
 “Intellectual Property” means any and all of the following in any jurisdiction throughout the world: (i) trademarks, service marks, trade names, brand names, logos, trade dress, design rights, and other similar designations of source, sponsorship, association or origin, together with the goodwill connected with the use of and symbolized by, and all registrations, applications, and renewals for, any of the foregoing; (ii) copyrights, including all applications and registrations related to the foregoing; (iii) trade secrets and confidential know-how; (iv) patents and patent applications; (v) internet domain names, whether or not trademarks, registered in any top-level domain by any authorized private registrar or governmental authority, web addresses, web pages, websites and related content, accounts with social media companies and the content found thereon and related thereto, and URLs; and (vi) other intellectual property and related proprietary rights, interests, and protections (including all rights to sue, recover, and retain damages, costs, and attorneys’ fees for past, present, and future infringement and any other rights relating to any of the foregoing). 
 (r)
 “Liens” means, respecting any property or asset, any mortgage, lien, pledge, charge, security interest, claim, encumbrance, royalty interest, any other adverse claim of any kind concerning such property or asset or any other restrictions or limitations of any nature whatsoever.
 (s)
 “Material Adverse Effect” means any event, change, or effect that has or would have a materially adverse effect on the financial condition, business, or results of operations of an entity or group of entities, taken as a whole. 
 

 2
 

 
 
 (t)
 “Nevada Law” means laws governing corporations under the Nevada Revised Statutes, as amended. 
 (u)
 “Person” means an individual, corporation, partnership, limited liability company, association, trust, unincorporated organization, other entity, or group. 
 (v)
 “Purchaser” means Zeuus, Inc., a Nevada corporation.
 (w)
 “Purchaser Representatives” has the meaning specified in subsection 8.03(b). 
 (x)
 “Required Consents” has the meaning specified in section 3.07.
 (y)
 “SEC” means the United States Securities and Exchange Commission. 
 (z)
 “SEC Reports” has the meaning specified in section 4.04. 
 (aa)
 “Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.
 (bb)
 “Seller” and “Sellers” have the meanings specified in the preamble.  
 (cc)
 “Sellers Disclosure Schedules” has the meaning specified in Article 3. 
 (dd)
 “Sellers Representatives” has the meaning specified in subsection 8.03(a). 
 (ee)
 “Tax” (and, with correlative meanings, “Taxes” and “Taxable”) means any: 
 (i)
 income tax; alternative or add-on minimum tax; gross receipts tax; sales tax; use tax; ad valorem tax; transfer tax; franchise tax; profits tax; license tax; withholding tax; payroll tax; employment tax; excise tax; severance tax; stamp tax; occupation tax; property tax; environmental or windfall profit tax; custom, duty or other tax; impost; levy; governmental fee; or other like assessment or charge of any kind whatsoever, together with any interest, penalty, or additional amount imposed with respect thereto by any governmental or Tax authority responsible for the imposition of any such tax (domestic or foreign); 
 (ii)
 liability for the payment of any amounts of the type described in clause (a) above as a result of being a member of an affiliated, consolidated, combined, or unitary group for any Taxable period; and 
 (iii)
 liability for the payment of any amounts of the type described in clauses (i) or (ii) above as a result of any express or implied obligation to indemnify any other Person. 
 (ff)
 “Tax Return” means any return, report, declaration, form, claim for refund, or information return or statement relating to Taxes, including any schedule or attachment thereto and any amendment thereof.
 (gg)
 “Wind Turbine Technology” means the innovative wind turbine technology using the concentration of wind stream, which increases the efficacy of wind turbines in weak and medium winds, including all Intellectual Property (defined below), code, other intangibles, and all related documentation associated with the Wind Turbine Technology. 
 

 3
 

 
 
 (hh)
 “Zeuus Stock” means Purchaser’s common stock. 
 Section 1.02
 Interpretation. The language in all parts of this APA will be in all cases construed simply according to its fair meaning and not strictly for or against any Party. Section headings contained in this APA are for reference purposes only and will not affect the meaning or interpretation of this APA. Except when the context clearly requires to the contrary: (a) all references in this APA to designated “sections” are to the designated sections and other subdivisions of this APA; (b) instances of gender or entity-specific usage (e.g., “his,” “her,” “its,” or “individual”) will not be interpreted to preclude the application of any provision of this APA to any individual or Person; (c) the word “or” will not be applied in its exclusive sense, unless the context otherwise requires; (d) “including” will mean that the items listed are illustrative and without limitation on the antecedent reference, without any implication that all or even most of the components are mentioned; (e) references to laws, regulations, and other governmental rules (collectively, “rules”), as well as to contracts, agreements, and other instruments (collectively, “instruments”), will mean such rules and instruments as in effect at the time of determination (taking into account any amendments thereto effective at such time without regard to whether such amendments were enacted or adopted after the effective date) and will include all successor rules and instruments thereto; (f) references to “$,” “cash,” or “dollars” will mean the lawful currency of the United States; (g) unless otherwise indicated, periods within which a payment is to be made or any other action is to be taken hereunder will be calculated excluding the day on which the period commences and including the day on which the period ends; (h) references to “federal” will be to laws, agencies, or other attributes of the United States (and not to any state or locality thereof); (i) the meaning of the terms “domestic” and “foreign” will be determined by reference to the United States; (j) if any day specified in this APA for any notice, action, or event is not a business day, then the due date for such notice, action, or event will be extended to the next succeeding business day; (k) references to “days” will mean calendar days; references to “business days” will mean all days other than Saturdays, Sundays, and days that are legal holidays in the state of New York; (l) references to monthly or annual anniversaries will be to the actual calendar months or years at issue (without taking into account the actual number of days in any such month or year); (m) days, business days, and times of day will be determined by reference to local time in New York; (n) the English language version of this APA and all documents or instruments delivered by any Party hereto will govern all questions of interpretation relating to this APA, notwithstanding that this APA may have been translated into, and executed in, other languages; (o) whenever in this APA a Person is permitted or required to make a decision in its “discretion” or under a grant of similar authority or latitude, such Person will be entitled to consider only such interests and factors as it deems appropriate, in its absolute discretion; and (p) whenever in this APA a Person or group is permitted or required to make a decision in its “good faith” or under another express standard, the Person will act under such express standard and will not be subject to any other or different standard imposed by this APA or other Applicable Law.
 Article 2
 Acquisition of Assets; Purchase Price
 Section 2.01
 Purchase and Sale of Assets. On the Closing Date and subject to the terms and conditions of this APA, Sellers hereby irrevocably sell, convey, transfer, assign, and deliver to Purchaser, and Purchaser hereby purchases from Sellers, all of Sellers’ right, title, and interest, as applicable, in and to all of the Acquired Assets, but excluding the Excluded Assets in each case, at and as of the Closing Date, free and clear of all Liens. 
 Section 2.02
 Acquired Assets. Subject to section 2.03, the “Acquired Assets” consist of all of the assets of Sellers that are listed on Exhibit A and the General Assignment and Bill of Sale (“Bill of Sale”) in substantially the form attached hereto as Exhibit B.
 

 4
 

 
 
 Section 2.03
 Excluded Assets. Notwithstanding anything to the contrary in this APA, the following specified rights, properties, claims, and assets will be retained by Sellers and will be excluded from the Acquired Assets (collectively, the “Excluded Assets”). The Excluded Assets are:
 (a)
 accounts receivable relating to the Acquired Assets as of the Closing Date; and
 (b)
 all liabilities of Sellers relating to the Acquired Assets existing as of the Closing Date. 
 Section 2.04
 Retained Liabilities. Purchaser will not assume or be obligated to pay, perform, or otherwise discharge any liability or obligation of Sellers or any of their respective affiliates of any kind whatsoever, whether, accrued, direct or indirect, known or unknown, absolute or contingent. 
 Section 2.05
 Purchase Price and Payment. As consideration for the sale of the Acquired Assets and other commitments of Sellers set forth in this APA, on the Closing Date, Purchaser will: (a) wire transfer $100,000 in immediately available funds to an account designated by Sellers; and (b) issue to each Seller $266,667 worth of Zeuus Stock based on the average of the closing price per share of Zeuus Stock for the 30 trading days prior to the Effective Date.  
 Section 2.06
 Instruments of Transfer; Further Assurances. At the Closing, Sellers and Purchaser will each deliver to the other executed counterparts of this APA and the Bill of Sale conveying all of the Acquired Assets to Purchaser. At the Closing, and at all times thereafter as may be necessary, Sellers (at Sellers’ expense) will execute and deliver to Purchaser: (a) such other instruments of transfer as are reasonably necessary or appropriate to vest in Purchaser good and indefeasible title to the Acquired Assets and to comply with the purposes and intent of this APA; and (b) such other instruments as are reasonably necessary or appropriate to evidence the assignment by Sellers and assumption by Purchaser of the Acquired Assets to the extent provided in Article 2.
 Section 2.07
 Nonassignability. Notwithstanding any other provision of this APA, this APA will not be deemed to constitute an assignment of, or an agreement to assign, any Acquired Asset or any claim, right, or benefit arising thereunder or resulting therefrom if an assignment or attempted assignment thereof, without the consent of a third party with respect thereto, would constitute a breach or other contravention thereof or adversely affect the rights of Purchaser thereunder in any material respect. To the best of Sellers’ knowledge, there are is no Person other than Sellers with any claim or right to the Acquired Assets. Accordingly, Sellers will use commercially reasonable efforts to obtain the consent of any other Persons to any the Acquired Assets or any claim or right or any benefit arising thereunder for the assignment thereof to Purchaser as Purchaser may reasonably request in writing, including the Required Consents. Sellers will be solely responsible for all fees and expenses paid to third parties to obtain such consents. If any such consent is not obtained, or if an attempted assignment thereof would be ineffective or would adversely affect the rights of Purchaser therein in any material respect, Sellers will cooperate with Purchaser in entering into a mutually agreeable arrangement under which either: (a) Purchaser would in all material respects obtain the benefits, assume the obligations, and bear the economic burden thereunder in accordance with this APA, including subcontracting, sublicensing, or subleasing to Purchaser; or (b) Sellers would enforce for the benefit of Purchaser, at Sellers’ expense, any and all of their rights against any third party thereto, and Sellers would pay to Purchaser when received all monies received by them under any such Acquired Asset or any material claim, right, or benefit arising thereunder. 
 

 5
 

 
 
 Section 2.08
 Due Diligence and Closing. 
 (a)
 Commencing on the Effective Date, Purchaser will have 60 calendar days before the Closing Date to conduct its due diligence review of the Wind Turbine Technology in accordance with the terms and conditions of section 8.03.  
 (b)
 The closing of the purchase and sale of the Acquired Assets (the “Closing”) will occur on or before 6th June, 2021 (the “Closing Date”). Any extension of the Closing Date may be made only with the Parties’ mutual written consent. The Closing will take place by the exchange of documents and funds electronically, by facsimile, or via overnight courier by a recognized national courier service as soon as practicable (but in any event within two business days) after the satisfaction or, if permissible, waiver of the conditions set forth in Articles 5 and 6, or at such other date, time, and place as the Parties may agree. For all purposes hereof, the term “Effective Time” will be 12:01 a.m., Nevada time, on the Closing Date. Subject to Article 10, failure to consummate the Closing will not result in the termination of this APA or relieve any Person of any obligation hereunder. 
 Section 2.09
 Restrictions on Transfer of Shares. Transfer of the Zeuus Stock to Sellers in accordance with this APA will be subject to certain restrictions under the Securities Act and Regulation D promulgated by the SEC thereunder and certain applicable state securities laws. The Zeuus Stock must be held and may not be sold, transferred, or otherwise disposed of for value unless subsequently registered under the Securities Act or an exemption from such registration is available. Purchaser is under no obligation to register the Zeuus Stock under the Securities Act or under Section 12 of the Exchange Act, except as expressly agreed to in writing by Purchaser; and the certificates representing the Zeuus Stock will bear a legend so restricting the sale of such shares. 
 Section 2.10
 Lock-Up Period. Sellers agree to not offer, sell, contract to sell, pledge, hypothecate, grant any option to purchase or make any short sale of, or otherwise dispose of any shares of Zeuus Stock for the period commencing on the Closing Date and terminating 18 months thereafter. 
 Article 3
 Representations and Warranties of Sellers
 Each Seller hereby represents, covenants, and warrants as follows to Purchaser, such representations, covenants, and warranties to be made as of the date hereof and at and as of the Closing Date, to survive the Closing (except as otherwise expressly set forth in Article 7) and to continue in accordance with the terms hereof, as set forth in this Article 3 and as limited, qualified by, or except as otherwise set forth in the written disclosure schedules to this APA separately provided by Sellers to Purchaser (the “Sellers Disclosure Schedules”). 
 Section 3.01
 Authority. Sellers have all requisite power and authority to execute and deliver this APA, to perform their obligations hereunder, and to consummate the transactions contemplated hereby. The execution and delivery of this APA by Sellers and the consummation by Sellers of the transactions contemplated hereby have been duly authorized by all necessary action, and no other proceedings on the part of Sellers are necessary to authorize this APA or to consummate the transactions contemplated hereby. This APA has been duly executed and delivered by Sellers and, assuming the due authorization, execution, and delivery thereof by Purchaser, constitutes the legal, valid, and binding obligation of Sellers, enforceable against Sellers in accordance with its terms, except that: (a) such enforcement may be subject to applicable bankruptcy, insolvency, or other similar laws, now or hereafter in effect, affecting creditors’ rights generally; and (b) the remedy of specific performance and injunctive 
 

 6
 

 
 and other forms of equitable relief may be subject to equitable defenses and to the discretion of the court before which any proceeding therefor may be brought. 
 Section 3.02
 Title to Property. Except as described in Sellers Disclosure Schedule 3.02, Sellers have good and marketable title to all of the Acquired Assets, free and clear of all Liens. Upon delivery to Purchaser on the Closing Date of the instruments of transfer contemplated by Article V, Sellers will thereby transfer to Purchaser good and marketable title to the Acquired Assets being conveyed, free and clear of all Liens, except as described in Sellers Disclosure Schedule 3.02. 
 Section 3.03
 Intellectual Property. Exhibit A lists all of Sellers’ Intellectual Property included in the Acquired Assets. Sellers own or have adequate, valid, and enforceable rights to use all the Acquired Assets, free and clear of all Liens. Sellers are not bound by any outstanding judgment, injunction, order or decree restricting the use of the Acquired Assets or restricting the assignment or licensing thereof to any Person. With respect to the Intellectual Property listed on Exhibit A: (a) all such Intellectual Property is valid, subsisting, and in full force and effect; (b) Sellers have paid all maintenance fees and made all filings required to maintain Sellers’ ownership thereof; and (c) Sellers’ prior and current use of the Acquired Assets has not and does not infringe, violate, dilute, or misappropriate the Intellectual Property of any Person, and there are no pending or threatened proceedings, litigation, or other adverse claims by any Person respecting the ownership, validity, enforceability, effectiveness, or use of the Acquired Assets. No Person is infringing, misappropriating, diluting, or otherwise violating any of the Acquired Assets, and Sellers have not made or asserted any claim, demand, or notice against any Person alleging any such infringement, misappropriation, dilution, or other violation. Continuing use of the Acquired Assets as provided does not infringe, violate, dilute, or misappropriate the Intellectual Property of any Person, and the Acquired Assets comprise all rights necessary to permit the development and commercialization of the Wind Turbine Technology.
 Section 3.04
 Litigation and Proceedings. Except as set forth in Sellers Disclosure Schedule 3.04, there are no actions, suits, or proceedings pending or, to the knowledge of Sellers, threatened by or against, or affecting Sellers or their properties, at law or in equity, before any court or other governmental agency or instrumentality, domestic or foreign, or before any arbitrator of any kind; Sellers do not have any knowledge of any default on them, individually or collectively, with respect to any judgment, order, writ, injunction, decree, award, rule, or regulation of any court, arbitrator, or governmental agency or instrumentality. 
 Section 3.05
 Material Contract Defaults. Except as set forth in Sellers Disclosure Schedule 3.05, Sellers are not in default in any respect under the terms of any outstanding contract, agreement, lease, or other commitment that is material to the properties, assets, or condition of Sellers, and there is no event of default or other event that with notice or lapse of time, or both, would constitute a default in any material respect under any contract, agreement, lease, or other commitment for which Sellers have not taken adequate steps to prevent from occurring.
 Section 3.06
 Taxes. All federal, state, local, and foreign Tax Returns required to be filed by or on behalf of Sellers have been filed with the appropriate governmental agency and all jurisdictions in which such reports are required to be filed and all Taxes that have become due or payable pursuant to such Tax Returns or to any assessment have been paid. 
 Section 3.07
 Consents and Permits. Included in Sellers Disclosure Schedule 3.07 is a description of each contract, agreement, lease, or other commitment, written or oral, to which each Seller is a party or to which any of their respective properties or assets are subject pursuant to which the consent of the other party is required in order to consummate the transactions herein contemplated (the “Required Consents”), except when the failure to obtain such consent would not have a Material Adverse Effect on 
 

 7
 

 
 the Acquired Assets. Sellers will use their best efforts to obtain from all third parties any Required Consents in order to consummate the transactions contemplated by this APA. 
 Section 3.08
 No Conflict with Other Instruments. The execution of this APA and the consummation of the transactions contemplated by this APA will not result in the breach of any term or provision of, or constitute an event of default under, any material indenture, mortgage, deed of trust, or other material contract, agreement, or instrument to which a Seller is a party or to which any of their respective properties or activities are subject. 
 Section 3.09
 Compliance with Laws and Regulations. Sellers have complied with all applicable statutes and regulations of any federal, state, or other governmental entity or agency thereof, foreign or domestic, except to the extent that noncompliance would not materially and adversely affect the properties, assets, or condition of Sellers or except to the extent that noncompliance would not result in the incurrence of any material liability for Sellers. 
 Section 3.10
 Information. The information concerning Sellers set forth in this APA, in the exhibits hereto, and in the Sellers Disclosure Schedules is complete and accurate in all material respects and does not contain any untrue statement of a material fact or omit to state a material fact required to make the statements made, in light of the circumstances under which they were made, not misleading. 
 Section 3.11
 Liabilities and Obligations. 
 (a)
 Except to the extent disclosed in Sellers Disclosure Schedule 3.11(a), no liabilities or obligations of any nature (whether accrued, absolute, contingent, or otherwise) are secured by a Lien on any of Sellers’ assets. 
 (b)
 Except as set forth Sellers Disclosure Schedule 3.11(b), no Person with which a Seller is affiliated is indebted to Sellers, and Sellers have no indebtedness or liability to any member, shareholder, or corporation or entity with which they are affiliated.
 (c)
 Sellers are not in default under any evidence of indebtedness for borrowed money. 
 Section 3.12
 Validity of APA. Neither the execution and the delivery of this APA nor the performance of any of the covenants or obligations to be performed hereunder by Sellers will: (a) result in any violation of any order, decree, or judgment of any court or other governmental body or Applicable Law by Sellers; or (b) constitute a default under any indenture, mortgage, deed of trust, or other contract to which a Seller is a party or by which a Seller is bound. 
 Section 3.13
 Completeness of Representations and Schedules. 
 (a)
 Sellers Disclosure Schedules and exhibits hereto completely and correctly present in all material respects the information required by this APA. This APA, any Sellers Disclosure Schedules, and exhibits to be delivered under this APA; the representations and warranties of this Article 3; and the documents and written information pertaining to Sellers furnished to Purchaser or the Purchaser Representatives do not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements made, in the light of the circumstances under which they were made, not misleading. 
 (b)
 Sellers will promptly notify Purchaser of any event or change in circumstances that contradicts the representations that Sellers has made in this Article 3 or if Sellers are subject 
 

 8
 

 
 to any material events that may affect their ongoing activities or the Acquired Assets, such as litigation or financial distress.
 Section 3.14
 Finder’s Fees. No broker or investment banker is entitled to any brokerage, finder’s, or other fee or commission in connection with the transactions contemplated by this APA based upon arrangements made by or on behalf of Sellers. 
 Article 4
 Representations and Warranties of Purchaser
 Purchaser hereby represents, covenants, and warrants as follows to Sellers, such representations, covenants, and warranties to be made as of the date hereof and at and as of the Closing Date, to survive the Closing (except as otherwise expressly set forth in Article 7) and to continue in accordance with the terms hereof, as set forth in this Article 4. 
 Section 4.01
 Authority. Purchaser has all requisite corporate power and authority to execute and deliver this APA, to perform its obligations hereunder, and to consummate the transactions contemplated hereby. The execution and delivery of this APA by Purchaser and the consummation by Purchaser of the transactions contemplated hereby have been duly authorized by all necessary corporate action, and no other corporate proceedings on the part of Purchaser are necessary to authorize this APA or to consummate the transactions contemplated hereby. This APA has been duly executed and delivered by Purchaser and, assuming the due authorization, execution, and delivery thereof by Sellers, constitutes the legal, valid, and binding obligation of Purchaser, enforceable against Purchaser in accordance with its terms, except that: (a) such enforcement may be subject to applicable bankruptcy, insolvency, or other similar laws, now or hereafter in effect, affecting creditors’ rights generally; and (b) the remedy of specific performance and injunctive and other forms of equitable relief may be subject to equitable defenses and to the discretion of the court before which any proceeding therefor may be brought. 
 Section 4.02
 Organization and Good Standing. Purchaser is a corporation duly organized and existing in good standing under Nevada Law. Purchaser has full corporate power and authority to carry on its business as now conducted. Purchaser is duly qualified to transact business in the state of Nevada and in all states and jurisdictions in which its business or ownership of its properties or assets makes it necessary so to qualify (other than in jurisdictions in which the nature of the property owned or business conducted, when considered in relation to the absence of serious penalties, renders qualification as a foreign corporation unnecessary as a practical matter).
 Section 4.03
 Capitalization. The authorized capital stock of Purchaser consists of 75,000,000 shares of common stock, par value $0.001 per share. As of the date of this APA, approximately 10,530,000 shares of common stock (or Zeuus Stock) are issued and outstanding. The issued and outstanding shares of common stock are validly issued, fully paid, nonassessable, and subject to no restrictions on transfer other than Securities Act restrictions applicable to restricted securities. There are no treasury shares. 
 Section 4.04
 Filings; Financial Statements. 
 (a)
 True and complete copies of all Annual Reports on Form 10-K; all Quarterly Reports on Form 10-Q; all proxy, information, or consent solicitation statements relating to meetings of shareholders or consents in lieu thereof (whether annual or special); all Current Reports on Form 8-K; and all other reports, schedules, registration statements, or other documents, and amendments thereto, filed with the SEC by Purchaser since its inception (the “SEC Reports”) are available to Sellers through the SEC’s website at www.sec.gov. Purchaser 
 

 9
 

 
 has filed all forms, reports, statements, and other documents required to be filed with: (i) the SEC, including the SEC Reports; (ii) any applicable state securities authorities; and (iii) any other applicable federal, state, or local regulatory authorities; except when the failure to file any such forms, reports, statements, or other documents would not have a Material Adverse Effect. As of their respective dates, or as of the date of the last amendment thereof if amended after filing, none of the SEC Reports (including all schedules thereto and disclosure documents incorporated by reference therein) contained any untrue statement of a material fact or omitted a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading. Each of the SEC Reports as of the time of filing, or as of the date of the last amendment thereof if amended after filing, complied in all material respects with the Exchange Act or the Securities Act, as applicable. 
 (b)
 Purchaser has made all filings and reports required under all Applicable Laws respecting its business and any predecessor entity, except filings and reports in those jurisdictions in which the nature of the property owned or business conducted, when considered in relation to the absence of serious penalties, renders the required filings or reports unnecessary as a practical matter. 
 (c)
 The consolidated financial statements of Purchaser included in the SEC Reports fairly present, in conformity in all material respects with GAAP, the consolidated financial position of Purchaser as of the dates thereof and the consolidated results of operations and changes in financial position for the periods then ended. 
 Section 4.05
 Liabilities and Obligations. 
 (a)
 Except to the extent set forth in Purchaser’s financial statements or disclosed in its SEC Reports, Purchaser has no liabilities or obligations of any nature (whether accrued, absolute, contingent, or otherwise) secured by a Lien on any of its assets. 
 (b)
 Except as set forth in Purchaser’s financial statements, no Person with which Purchaser is affiliated is indebted to Purchaser, and Purchaser has no indebtedness or liability to any shareholder or any Person with which it is affiliated. 
 (c)
 Except to the extent set forth in Purchaser’s financial statements or disclosed in its SEC Reports, Purchaser is not in default under any evidence of indebtedness for borrowed money. 
 Section 4.06
 Taxes. Purchaser has filed all Tax Returns or forms that are required to be filed since its inception. No Taxes are due to any federal, state, local, or foreign Tax authority. Purchaser is not obligated to make any payments and is not a party to any agreement that under any circumstances could obligate it to make any payments that will not be deductible under Section 280G of the Code. 
 Section 4.07
 Compliance with Securities Laws, Rules, and Regulations. All securities of Purchaser issued since its inception have been issued pursuant to and in compliance with Applicable Laws; specifically, all offers and sales of shares of common stock were registered with the SEC or made pursuant to exemptions from the registration requirements of Section 5 of the Securities Act and available exemptions provided by applicable state securities laws. 
 Section 4.08
 Validity of APA. Neither the execution and the delivery of this APA nor the performance of any of the covenants or obligations to be performed hereunder by Purchaser will: (a) result in any violation of any order, decree, or judgment of any court or other governmental body or 
 

 10
 

 
 Applicable Law by Purchaser; (b) result in any breach of any terms or provisions of Purchaser’s articles of incorporation or bylaws; or (c) constitute a default under any indenture, mortgage, deed of trust, or other contract to which Purchaser is a party or by which Purchaser is bound.  
 Section 4.09
 Completeness of Representations and Schedules. 
 (a)
 The SEC Reports, this APA and exhibits to be delivered under this APA; the representations and warranties of this Article 4; and the documents and written information pertaining to Purchaser furnished to Sellers or the Sellers Representatives completely and correctly present in all material respects the information required by this APA and do not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements made, in the light of the circumstances under which they were made, not misleading. 
 (b)
 Purchaser will promptly notify Sellers of any event or change in circumstances that contradicts the representations that Purchaser has made in this Article 4, or if Purchaser is subject to any material events that may affect its ongoing business operations, such as litigation or financial distress.
 Section 4.10
 Finder’s Fees. No broker or investment banker is entitled to any brokerage, finder’s, or other fee or commission in connection with the transactions contemplated by this APA based upon arrangements made by or on behalf of Purchaser. 
 Article 5
 Conditions Precedent to the Obligations of Purchaser
 The obligations of Purchaser pursuant to this APA are, at the option of Purchaser, subject to the fulfillment, on or before the Closing Date, of the following conditions:
 (a)
 Sellers have duly executed and delivered this APA, the Bill of Sale, and the Executive Employment Agreements to Purchaser, and all requisite action required to consummate the transactions contemplated hereby has been duly and validly taken by Sellers.
 (b)
 All representations and warranties of Sellers contained in this APA are true in all material respects as of the Closing Date. 
 (c)
 Sellers have performed and complied with all agreements, terms, and conditions required by this APA to be performed or complied with by them. 
 (d)
 No action or proceeding before any court or other governmental body has been instituted that prohibits or invalidates, or threatens to prohibit or invalidate, the transactions contemplated by this APA.
 (e)
 Purchaser has received Sellers Disclosure Schedules, which are acceptable in form and content to Purchaser. 
 Article 6
 Conditions Precedent to the Obligations of Sellers
 The obligations of Sellers under this APA are, at the option of Sellers, subject to the fulfillment to Sellers’ satisfaction on or before the Closing Date of each of the following conditions:
 

 11
 

 
 
 (a)
 Purchaser has duly executed and delivered this APA, the Bill of Sale, and the Employment Agreements to Sellers, and all corporate action required to consummate the transactions contemplated hereby has been duly and validly taken by Purchaser.
 (b)
 The representations and warranties made to Sellers in this APA or in any document, statement, list, or certificate furnished pursuant hereto are true and correct as of the Closing Date.
 (c)
 Purchaser has no contingent or other liabilities connected with its business, except as disclosed in the financial statements included in the SEC Reports or that otherwise have been incurred in the ordinary course of business. 
 (d)
 The review of Purchaser’s business, premises, operations, and financial statements by Sellers, at their expense, is satisfactory to Sellers and has not revealed any matter that, in the sole judgment of Sellers, makes the transactions on the terms herein set forth inadvisable for Sellers. 
 (e)
 The transactions contemplated by this APA have been duly approved by Purchaser’s board of directors pursuant to Nevada Law.
 (f)
 Purchaser has filed all required periodic reports under the Exchange Act and has made all other such filings with the SEC and state securities regulators as may be required by Applicable Law. 
 (g)
 No action or proceeding before any court or other governmental body has been instituted that prohibits or invalidates, or threatens to prohibit or invalidate, the transactions contemplated by this APA. 
 Article 7
 Survival
 Section 7.01
 Representations and Warranties. The representations and warranties made by the Parties in this APA and all of the covenants of the Parties in this APA will survive the execution and delivery of this APA and the Closing Date and will expire on the two-year anniversary of the Closing Date. Any claim for indemnification will be effective only if notice of such claim is given by the Party claiming indemnification or other relief on or before the 24-month anniversary of the Closing Date. 
 Section 7.02
 Obligations under APA. If the Purchaser or any of its successors or assigns consolidates with or merges into any other entity and will not be the continuing or surviving corporation or if the Purchaser or any of properties and assets are sold to another Person, then, and in each such case, proper provisions will be made in the governing documents so that the successors and assigns of Purchaser, the surviving corporation, or the buyer of Purchaser’s properties or assets, as applicable, will assume all of the obligations of Purchaser set forth in this APA.
 Article 8
 Certain Covenants and Additional Agreements of the Parties
 Section 8.01
 Approval of Sellers. The consummation of this APA and the transactions contemplated herein, including the issuance of the Zeuus Stock, constitute the offer and sale of securities under the Securities Act and applicable state securities laws. In order to provide documentation for reliance upon exemptions from the registration and prospectus delivery requirements for such 
 

 12
 

 
 transactions, Sellers will be required to acknowledge and represent in writing their acceptance of, and concurrence in, among other things, the approval of the transactions contemplated by this APA and the acceptance and receipt of the Zeuus Stock pursuant to this APA. Sellers acknowledge that such transactions will be consummated in reliance on the exemption from registration under Section 4(a)(2) of the Securities Act and Rule 506 promulgated thereunder and preemption from the securities registration or qualification requirements (other than notice filing and fee provisions) of applicable state laws under the National Securities Markets Improvement Act of 1996 or exemption from such state registration requirements.
 Section 8.02
 Effectiveness of Representations, Warranties, and Agreements. Prior to the execution of this APA, each Party has made available to the other Parties the opportunity to review any disclosures made pursuant to this APA and other information available in accordance with the provisions of this APA. Each Party has been afforded the opportunity to engage its or his own attorneys, accountants, and other advisers to assist in the review of such schedules and other information and has made its or his own decision respecting the extent to which such Party has engaged such attorneys, accountants, and other advisers. The representations, warranties, and agreements of each Party will remain operative and in full force and effect regardless of any investigation made by or on behalf of the other Parties, any Person controlling such Party, or any of its or his officers, directors, managers, members, partners, representatives, attorneys, accountants, or agents, whether before or after the execution of this APA.
 Section 8.03
 Access and Information. 
 (a)
 Purchaser will: (i) afford Sellers and their respective accountants, consultants, legal counsel, agents, and other representatives (collectively, the “Sellers Representatives”) reasonable access at reasonable times, upon reasonable prior notice, to the officers, directors, employees, agents, properties, offices, and other facilities of Purchaser (including any subsidiary) and to the books and records thereof; and (ii) furnish promptly to Sellers and Sellers Representatives such information concerning the business, properties, contracts, records, and personnel of Purchaser (including financial, operating, and other data and information) as may be reasonably requested, from time to time, by Sellers and Sellers Representatives.
 (b)
 Sellers will: (i) afford to Purchaser and its officers, directors, employees, accountants, consultants, legal counsel, agents, and other representatives (collectively, the “Purchaser Representatives”) reasonable access at reasonable times, upon reasonable prior notice, to the accountants, agents, and other representatives of Sellers; and (ii) furnish promptly to Purchaser and the Purchaser Representatives such information concerning the properties, contracts, and records of Sellers (including financial, operating, and other data and information) as may be reasonably requested, from time to time, by Purchaser and the Purchaser Representatives.
 (c)
 Notwithstanding the foregoing provisions of this section, no Party will be required to grant access or furnish information to the other Parties to the extent that such access to or the furnishing of such information is prohibited by Applicable Law. No investigation by the Parties made heretofore or hereafter will affect the representations and warranties of the Parties that are herein contained, and each such representation and warranty will survive such investigation.
 (d)
 Each Party agrees that it or he will treat in confidence all documents, materials, and other confidential information that it or he will have obtained regarding the other Parties during the course of the negotiations leading to the consummation of the transactions contemplated hereby (whether obtained before or after the date of this APA), the investigation 
 

 13
 

 
 provided for herein, and the preparation of this APA and other related documents (collectively, the “Confidential Information”). Such Confidential Information will not be communicated to any third Person (other than to such Party’s respective counsel, accountants, financial advisers, or lenders) and will not be used for any purpose to the detriment of the other Parties. No Party will use any Confidential Information in any manner whatsoever except solely for the purpose of evaluating a possible business relationship with the other Parties. No Party and no Sellers Representative or Purchaser Representative will, during the term of this APA or at any time during the two years thereafter, irrespective of the time, manner, or cause of termination of this APA, use, disclose, copy, or assist any other Person in the use, disclosure, or copying of any Confidential Information of the other Parties.
 Section 8.04
 No Representation or Opinions Regarding Certain Legal Matters. 
 (a)
 No representation or warranty is being made or legal opinion given by any Party to the other Parties regarding the treatment of this transaction for federal or state income taxation. Each Party has relied exclusively on its or his own legal, accounting, and other Tax advisers regarding the treatment of this transaction for federal and state income Taxes and on no representation, warranty, or assurance from any other Parties or such other Parties’ legal, accounting, or other advisers.
 (b)
 Notwithstanding the covenants respecting reliance on an exemption from registration under the Securities Act and limited preemption under Applicable Laws set forth in this Article 8, each Party acknowledges that it or he has relied exclusively on its or his own legal advisers regarding the availability of such exemption and preemption and on no representation, warranty, or assurance from any other Parties or such other Parties’ legal advisers. Inasmuch as the basis for relying on exemptions is factual, depending on the conduct of the Parties and their representatives in connection with the transactions contemplated by this APA, the Parties will not receive a legal opinion to the effect that the transactions contemplated by this APA and the issuance of the Zeuus Stock are exempt or preempted from registration under any federal or state law. Instead, the Parties will rely on the operative facts as documented by them as their basis for such exemptions. 
 Section 8.05
 Further Assurances. Each Party will use all reasonable efforts to: (a) take, or cause to be taken, all appropriate action, and do, or cause to be done, all things necessary, proper, or advisable under Applicable Laws or otherwise to consummate and make effective the transactions contemplated by this APA; (b) obtain from any governmental entities any consents, waivers, Authorizations, or orders required to be obtained or made by them or any subsidiary in connection with the authorization, execution, and delivery of this APA and the consummation of the transactions contemplated hereby; (c) make all necessary filings, and thereafter make any other required submissions, respecting this APA required under: (i) the Securities Act and the Exchange Act, and the rules and regulations thereunder, and any other applicable federal or state securities laws; and (ii) any other Applicable Law. Each Party agrees to cooperate with the other Parties in connection with the making of all such filings, including providing copies of all such documents to the other Parties and their respective advisers prior to the filings, and if requested, each Party agrees to accept all reasonable additions, deletions, or changes suggested in connection therewith. Each Party will furnish all information required for any application or other filing to be made pursuant to the rules and regulations of any Applicable Law in connection with the transactions contemplated by this APA.
 Section 8.06
 Allocation of Consideration. The allocation of the consideration paid among the Acquired Assets will be determined in accordance with Section 1060 of the Code. For purposes of and consistent with Section 1060 of the Code, the fair market value of such assets and the allocation of the 
 

 14
 

 
 consideration among the Acquired Assets will be determined by mutual agreement of the Parties. If the Parties are unable to agree as to an allocation, the allocation will be determined by a third party mutually selected by the Parties. All Tax Returns filed by the Parties respecting the transactions contemplated by this APA will be consistent with such allocation. Purchaser and Sellers will thereafter file all Tax Returns and information reports (including any Form 8594, Asset Acquisition Statement under Section 1060 of the Code) in a manner consistent with such allocation and will take no position inconsistent therewith. 
 Section 8.07
 Sales and Transfer Taxes.
 (a)
 Sellers will be liable for and will pay all Taxes (whether assessed or unassessed) applicable to the Acquired Assets conveyed hereunder attributable to periods (or portions thereof) ending on or prior to the Closing Date. Purchaser will be liable for and will pay all Taxes (whether assessed or unassessed) applicable to the Acquired Assets conveyed hereunder attributable to periods (or portions thereof) beginning after the Closing Date.
 (b)
 Notwithstanding subsection (a) above, any Tax (excluding any income tax) directly attributable to the sale or transfer of the Acquired Assets will be paid by Sellers.
 (c)
 Sellers or Purchaser, as the case may be, will provide reimbursement for any Tax paid by one Party when all or a portion of which is the responsibility of the other Parties in accordance with the terms of this section 8.07. Within a reasonable time prior to the payment of any Tax, the Party paying such Tax will give notice to the other Parties of the Tax payable and the portion that is the liability of each Party, although failure to do so will not relieve the other Parties from their liability hereunder.
 Section 8.08
 Expenses and Fees. Each Party will be solely responsible for its or his own costs and expenses (including legal expenses, accounting expenses, and brokers or finders’ fees and expenses), and the costs and expenses of its affiliates (if any), in connection with the preparation and negotiation of this APA and the consummation of the transactions contemplated by this APA. No Party will have any obligation for paying such expenses or costs of any other Party.
 Section 8.09
 Additional Agreements and Covenants of the Parties; Executive Employment Agreements. Purchaser will employ Andrei Seleznev as its Vice President of Operations, Nikolay Alekseev as its Chief Design Engineer, and Ilia Alekseev, as its Production Manager to further develop the Wind Turbine Technology and Acquired Assets under the terms of their respective Executive Employment Agreements in substantially the form attached hereto as Exhibits C-1, C-2, and C-3. 
 Article 9
 Indemnification
 Section 9.01
 Indemnification by Sellers. Sellers will defend, indemnify, and hold harmless Purchaser and its affiliates and their respective stockholders, directors, officers, members, managers, and employees from and against all claims, judgments, damages, liabilities, settlements, losses, costs, and expenses, including attorneys’ fees and disbursements, arising from or relating to any:
 (a)
 inaccuracy in or breach of any of the representations or warranties of Sellers contained in this Agreement or any document to be delivered hereunder; or
 (b)
 breach or nonfulfillment of any covenant, agreement, or obligation to be performed by Sellers pursuant to this Agreement or any document to be delivered hereunder.
 

 15
 

 
 
 Section 9.02
 Indemnification Procedures. Whenever any claim arises for indemnification hereunder, the Party entitled to indemnification (the “Indemnified Party”) will promptly provide written notice of such claim to the other Party (the “Indemnifying Party”). In connection with any claim giving rise to indemnity hereunder resulting from or arising out of any legal action by a Person that is not a party to this APA, the Indemnifying Party, at its sole cost and expense and upon written notice to the Indemnified Party, may assume the defense of any such legal action with counsel reasonably satisfactory to the Indemnified Party. The Indemnified Party will be entitled to participate in the defense of any legal action, with its counsel and at its own cost and expense. If the Indemnifying Party does not assume the defense of any such legal action, the Indemnified Party may, but will not be obligated to, defend against the legal action in such manner as it may deem appropriate, including settling the legal action, after giving notice of its intention to settle to the Indemnifying Party, on such terms as the Indemnified Party may deem appropriate, and no action taken by the Indemnified Party in accordance with the defense and settlement will relieve the Indemnifying Party of its indemnification obligations herein provided for any damages resulting therefrom. The Indemnifying Party will not settle any legal action without the Indemnified Party’s prior written consent (which consent shall not be unreasonably withheld or delayed).
 Section 9.03
 Cumulative Remedies. The rights and remedies provided in this Article 9 are cumulative and are in addition to and not in substitution for any other rights and remedies available at law or in equity or otherwise
 Article 10
 Termination
 Section 10.01
 Termination. Anything contained in this APA to the contrary notwithstanding, this APA may be terminated at any time prior to the Closing Date, by:
 (a)
 the mutual consent of the Parties; 
 (b)
 Purchaser in the event of any material breach by Sellers of any of the agreements, representations, or warranties of Sellers contained herein and the failure of Sellers to cure such breach within seven days after receipt of notice from Purchaser requesting such breach to be cured; or
 (c)
 Sellers in the event of any material breach by Purchaser of any of the agreements, representations, or warranties of Purchaser contained herein and the failure of Purchaser to cure such breach within seven days after receipt of notice from Sellers requesting such breach to be cured.
 Section 10.02
 Notice of Termination. Any Party desiring to terminate this APA pursuant to section 10.01 will give notice of such termination to the other Parties to this APA.
 Section 10.03
 Effect of Termination. In the event that this APA is terminated pursuant to this Article 10, all further obligations of the Parties under this APA (other than sections 8.03 and 8.08) will be terminated without further liability of any Party to the other Parties. But nothing herein will relieve any Party from liability for its or his willful breach of this APA.
 

 16
 

 
 Article 11
 Miscellaneous
 Section 11.01
 Successors and Assigns. This APA will be binding upon, inure to the benefit of, and be enforceable by the Parties and their permitted successors and assigns. No Party will assign its or his rights and obligations under this APA without the written consent of the other Parties. 
 Section 11.02
 Entire Agreement. This APA and its exhibits and schedules represent the entire agreement among the Parties relating to the subject matter hereof, and no other course of dealing, understanding, other agreement, covenant, representation, or warranty, written or oral, except as set forth herein or in the documents to be delivered in connection with the transactions contemplated hereby, the forms of which are attached hereto as exhibits, will be of any force or effect. Any previous agreement, arrangement, understanding, or course of dealing is expressly merged into this APA. No amendment or modification hereof will be effective until and unless the same will have been set forth in writing and signed by the Parties.
 Section 11.03
 Additional Documents. Each Party will cooperate in good faith and with diligence and dispatch in preparing any additional or confirmatory documents requested by any other Party in order to effectuate the terms and conditions of this APA.
 Section 11.04
 Notices. Any notice, demand, request, or other communication permitted or required under this APA will be in writing and will be deemed to have been given as of the date so delivered, if personally delivered; as of the date so sent, if sent by electronic mail and receipt is acknowledged by the recipient; and one day after the date so sent, if delivered by overnight courier service:
 If to Purchaser to: 
 Zeuss, Inc.
 Attn: Bassam Al Mutawa
 9th Floor, 31 West 27th Street
 New York, NY 10001
 USA
 

 with a copy to (which will not constitute notice):
 Michael Best & Friedrich LLP
 Attn: Terrell W. Smith
 170 S Main Street, Suite 1000
 Salt Lake City, UT 84101
 Phone: (385) 695-6450
 Email: twsmith@michaelbest.com 
 If to Sellers, to: 
 Andrei Seleznev
 [address and email redacted]
 Nikolay Alekseev
 [address and email redacted]
 Ilia Alekseev
 

 17
 

 
 [address and email redacted]
 Each Party may change its or his address by written notice in accordance with this section. 
 Section 11.05
 Nonwaiver. The rights and remedies of the Parties under this APA are cumulative and not alternative. Neither the failure nor any delay by any Party in exercising any right, power, or privilege under this APA will operate as a waiver of such right, power, or privilege, and no single or partial exercise of any such right, power, or privilege will preclude any other or further exercise of such right, power, or privilege or the exercise of any other right, power, or privilege. To the maximum extent permitted by Applicable Law: (a) no claim or right arising out of this APA can be discharged by one Party, in whole or in part, by a waiver or renunciation of the claim or right unless in writing signed by the other Parties; (b) no waiver that may be given by a Party will be applicable except in the specific instance for which it is given; and (c) no notice to or demand on one Party will be deemed to be a waiver of any obligation of such Party or of the right of the Party giving such notice or demand to take further action without notice or demand as provided in this APA. 
 Section 11.06
 Rules of Construction. The normal rules of construction that require the terms of an agreement to be construed most strictly against the drafter of such agreement are hereby waived since each Party has been represented by counsel in the drafting and negotiation of this APA.
 Section 11.07
 Third-Party Beneficiaries. Each Party intends this APA will not benefit or create any right or cause of action in or on behalf of any Person other than the Parties.
 Section 11.08
 Governing Law and Jurisdiction. This APA will be governed by, construed, interpreted, and enforced according to the laws of the state of Nevada, without giving effect to any choice or conflict of law provision or rule (whether the state of Nevada or any other jurisdiction) that would cause the application of the laws of any jurisdiction other than the state of Nevada. 
 Section 11.09
 Consent to Jurisdiction and Venue.
 (a)
 Each Party hereby consents to the jurisdiction of all state and federal courts located in Las Vegas, Nevada, as well as to the jurisdiction of all courts to which an appeal may be taken from such courts, for the purpose of injunctive relief in connection with this APA, including any proceeding relating to ancillary measures in aid of arbitration, provisional remedies, and interim relief or any proceeding to enforce any arbitral decision or award. Each Party hereby expressly waives any and all rights to bring any suit, action, or other proceeding in or before any court or tribunal other than the courts described above and covenants that it or he will not seek in any manner to resolve any dispute other than as set forth in this APA or to challenge or set aside any decision, award, or judgment obtained in accordance with the provisions hereof. 
 (b)
 Each Party hereby expressly waives any and all objections it or he may have to venue, including the inconvenience of such forum, in any of such courts. In addition, each Party consents to the service of process by personal service or any manner in which notices may be delivered hereunder in accordance with this APA. Notwithstanding the aforementioned waiver of venue objection, each Party mutually agrees to initially attempt to resolve any dispute in Nevada, subject to the governing law provided above, before relocating to an alternate venue if necessary.
 Section 11.10
 Waiver of Jury Trial. Each Party hereby voluntarily and irrevocably waives trial by jury in any action or other proceeding brought in connection with this APA or any of the transactions contemplated hereby.
 

 18
 

 
 
 Section 11.11
 Arbitration; Costs and Attorney Fees. Any dispute involving the interpretation, application, or enforcement of this APA will be submitted to binding arbitration before the American Arbitration Association, whose rules applicable to commercial disputes will apply except as modified by this section. The arbitration hearing will take place in Las Vegas, Nevada, before one arbitrator, who will be a retired judge (unless none is reasonably available). The arbitrator will submit written findings of fact and conclusions of law. The arbitrator will have authority only to interpret and apply provisions of this APA and will have no authority to add to, subtract from, or modify terms of this APA. The judgment of the arbitrator will be binding and may be entered as a final judgment by any court having jurisdiction over the Parties. In the event that any Party will initiate arbitration based on this APA, or take other permitted legal action for the enforcement or interpretation of any of the provisions of this APA, including such suit or action as may be necessary or germane to resolve or address any issues peculiar to federal bankruptcy law, the prevailing party in such action will, in addition to whatever judgment is rendered or award granted on its or his behalf, be entitled to its or his reasonable costs and expenses in connection with such action, including reasonable attorney’s fees.
 Section 11.12
 Severability. If any portion of this APA is finally determined by any court or governmental agency of competent jurisdiction to violate Applicable Law or otherwise not to conform to requirements of Applicable Law and, therefore, to be invalid, the Parties will cooperate to remedy or void the invalidity, but in any event, will not upset the general balance of relationships created or intended to be created between them as manifested by this APA and the instruments referred to herein. Except insofar as it would be an abuse of the foregoing principle, the remaining provisions hereof will remain in full force and effect.
 Section 11.13
 Time is of the Essence. Time is of the essence of this APA.
 Section 11.14
 Counterparts; Execution. This APA may be executed in multiple counterparts of like tenor, each of which will be deemed an original but all of which taken together will constitute one and the same instrument. Counterpart signatures of this APA that are manually signed and delivered by facsimile transmission; by a uniquely, marked computer-generated signature; or by other electronic methods, will be deemed to constitute signed original counterparts hereof and will bind the Parties signing and delivering in such manner and will be the same as the delivery of an original.
 IN WITNESS WHEREOF, the Parties have executed this APA as of the dates set forth below.
 PURCHASER:
 

 ZEUUS, INC.
 

 By: /s/ Bassam Al Mutawa
 Name: Bassam Al Mutawa
 Its: President and Chairman
 Date: 12/5/21
 

 SELLERS:
 

 /s/ Andrei Seleznev
 Andrei Seleznev
 Date: 12/5/21
 

 

 /s/ Nikolay Alekseev
 

 19
 

 
 Nikolay Alekseev
 Date: 12.05.2021
 

 /s/ Ilia Alekseev
 Ilia Alekseev
 Date: 12.05.2021
 

 20
 

 
 EXHIBIT A
 ACQUIRED ASSETS
 All Intellectual Property, code, and other intangibles and all related documentation associated with the Wind Turbine Technology application in its finished and developmental (raw code) states, including all that is expressly illustrated and described in the technical overview sheet that was developed as documentation for Wind Turbine Technology, the associated logins credentials to all necessary third-party systems, all plans, research, documents, programs, software, work-in-progress, designs, prototypes, experimental results, and related technical information underlying the origination and development of the Wind Turbine Technology.
 [Wind Turbine Technology Specifications excluded to 
 protect confidential and proprietary information]
 

 

 A-1
 

 
 

 

 EXHIBIT B
 GENERAL ASSIGNMENT AND BILL OF SALE
 THIS GENERAL ASSIGNMENT AND BILL OF SALE (this “Bill of Sale”) is made and entered into effective as of the date of the last signature (the “Effective Date”), by and among ANDREI SELEZNEV, NIKOLAY ALEKSEEV, and ILIA ALEKSEEV (“Assignors”), and ZEUUS, INC., a Nevada corporation (“Assignee”).
 Recitals
 Assignors and Assignee are parties to that certain Asset Purchase Agreement dated May 6th, 2021 (the “APA”). It is contemplated that this Bill of Sale will be entered into on the Closing Date by Assignors and Assignee pursuant to section 2.02 of the APA. The capitalized terms used in this Bill of Sale without definition have the meanings given them in the APA.
 Assignment
 NOW, THEREFORE, for in in consideration of the foregoing recital and mutual covenants, terms, and conditions contained herein, and for other good and valuable consideration, the receipt, adequacy, and sufficiency of which are hereby acknowledged, Assignors and Assignee agree as follows:
 1.
 Assignment. Assignors hereby assign, transfer, and convey to Assignee all of Assignors’ right, title, and interest in, and to the Acquired Assets, and all claims and causes of action accruing before or after the Effective Date related thereto whether accruing before, on, or after the Effective Date, including all rights of priority based on the Acquired Assets, and any and all patent or patents granted thereon, in, and to all rights of any kind whatsoever of Assignors accruing before, on, or after the Effective Date under any provisions provided by applicable law of any jurisdiction, by international treaties and conventions, and otherwise throughout the world; any and all claims and causes of action, respecting any of the foregoing, including all rights to and claims for damages, restitution, and injunctive and other legal and equitable relief for past, present, and future infringement, misappropriation, violation, misuse, breaches, or default, with the right to sue for such legal and equitable relief and to collect, or otherwise recover, any such damages.
 2.
 Further Assurances. Each of Assignors and Assignee covenants and agrees that, at any time and from time to time, it or he will do, execute, acknowledge, and deliver any and all other acts, deeds, assignments, transfers, conveyances, or other instruments necessary or proper to carry out the assignment and conveyance intended to be made hereby.
 3.
 Successors and Assigns. This Bill of Sale will be binding upon and inure to the benefit of Assignors and Assignee and their respective successors and assigns. 
 4.
 Counterparts; Execution. This Bill of Sale may be executed in multiple counterparts of like tenor, each of which will be deemed an original but all of which taken together will constitute one and the same instrument. Counterpart signatures of this Bill of Sale that are manually signed and delivered by facsimile transmission; by a uniquely, marked computer-generated signature; or by other electronic methods, will be deemed to constitute signed original counterparts hereof and will bind the Party signing and delivering in such manner and will be the same as the delivery of an original.
 

 B-1
 

 
 

 

 IN WITNESS WHEREOF, the parties have caused this Bill of Sale to be executed on the date set forth above.
  
 ASSIGNORS:
 

 /s/ Andrei Seleznev
 Andrei Seleznev
 Date: 12.05.21
 

 

 /s/ Nikolay Alekseev
 Nikolay Alekseev
 Date: 12.05.2021
 

 /s/ Ilia Alekseev
 Ilia Alekseev
 Date: 12.05.2021
 

 ASSIGNEE:
 ZEUUS, INC.
 

 By: /s/ Bassam Al Mutawa
 Name: Bassam Al Mutawa
 Its: President and Chairman
 Date: 12/5/21
 

 

 

 B-2
 

 
 

 

 

 EXHIBIT C
 FORM OF EXECUTIVE EMPLOYMENT AGREEMENT

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00327-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00327-of-00352.parquet"}]]